New epigenetic players in stroke pathogenesis: From non-coding RNAs to exosomal non-coding RNAs

Maryam Mahjoubin-Tehran#a,b, Samaneh Rezaei#, Amin Jesmani, Nafise Birang, Korosh Morshedi, Hashem Khanbabei, Haroon Khan, Ashkan Piranviseh#, Majid Nejati#, Michael Aschner, Hamed Mirzaei#, *

a Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran
b Department of Medical Biotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
c Department of Neurosurgery, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
d Department of Physical Medicine and Rehabilitation, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
e School of Medicine, Kashan University of Medical Sciences, Kashan, Iran
f Medical Physics Department, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran
g Department of Pharmacy, Abdul Wali Khan University, Mardan 23200, Pakistan
h Brain and Spinal Cord Injury Research Center, Tehran University of Medical Sciences, Tehran, Iran
i Anatomical Sciences Research Center, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran
j Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY 10463, USA
k Research Center for Biochemistry and Nutrition in Metabolic Diseases, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran

# These authors contributed equally to this work.

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Corresponding authors. ashkan.piran65@gmail.com (A. Piranviseh), Nejati-ma@kaums.ac.ir (M. Nejati), mirzaei-h@kaums.ac.ir (H. Mirzaei).
Author contributions
HM and MN contributed in conception, design, statistical analysis and drafting of the manuscript. MMT, SR, HKH, MA, HK, and KM contributed in data collection and manuscript drafting. AJ, NB, and AP contributed in the response to reviewer’s comments. All authors approved the final version for submission.

Conflict of interest statement
The other authors declare no conflicts of interest.
Availability of data and material
The primary data for this study is available from the authors on request.
Abstract

Non-coding RNAs (ncRNAs) have critical role in the pathophysiology as well as recovery after ischemic stroke. ncRNAs, particularly microRNAs, and the long non-coding RNAs (lncRNAs) are critical for angiogenesis and neuroprotection, and they have been suggested to be therapeutic, diagnostic and prognostic tools in cerebrovascular diseases, including stroke. Moreover, exosomes have been considered as nanocarriers capable of transferring various cargos, such as lncRNAs and miRNAs to recipient cells, with prominent inter-cellular roles in the mediation of neuro-restorative events following strokes and neural injuries. In this review, we summarize the pathogenic role of ncRNAs and exosomal ncRNAs in the stroke.

Keywords

Stroke; Long non-coding RNAs; MicroRNAs; Pathogenesis

1. Introduction

Stroke is a debilitating disease, and the 2nd main cause of global mortality. As stated by the WHO, almost 15 million people experience strokes worldwide, of which 5.5 million die each year [1]. Stroke prevalence, particularly in developing countries continues to grow, causing major social and economic burdens [2].

LncRNAs have key functions in various disorders. Numerous abnormally expressed lncRNAs are detected in patients with ischemic stroke or animal models of ischemia [3]. LncRNAs play a role in angiogenesis, inflammation, cell apoptosis and cell death. MicroRNAs (miRNAs) are a group of small non-coding RNAs [4]. Following stroke, miRNAs affect various pathophysiological mechanisms, such as hematopoiesis, proliferation or rapid growth, immune function, depression as well as metabolism [5]. Indeed, many investigations have corroborated the aberrant expression of miRNAs in stroke [5,6]. These studies establish miRNAs as key mediators in pathological and pathogenic features of ischemic stroke.

Exosomes are extra-cellular vesicles formed by fusion of multi-vesicular bodies with plasma membrane with subsequent release from cells. Exosomes are 30–100 nm in size, and express several cell-surface markers such as CD-63 and Alix. They are characterized by 1.13–1.19 g/mL density in sucrose and thus can be sedimented at 100,000 g [7]. Non-coding RNAs are released from cells in exosomes. Exosomal cargos, such as cellular proteins, non-coding RNAs(lncRNAs and miRNAs)and lipids act as mediators of inter-cellular cross-talk between recipient and effector cells [8]. Additionally, cargo preservation from degradation and transport across the blood-brain barrier (BBB) into the systemic circulation renders exosomes as potential disease biomarkers [9]. Exosomes contribute to neuro-inflammatory stress response as well as neurodegenerative diseases such as Parkinson’s disease (PD), stroke, Alzheimer ‘s disease (AD) and Schizophrenia [10]. Herein, we highlight the pathogenic role of non-coding RNAs in the stroke. Moreover, we summarize the role of exosomal non-coding RNAs in the stroke pathogenesis.
2. Biogenesis of IncRNAs

LncRNAs are important mediators of health and disease [11–17]. Several classes of lncRNAs exist, which are transcribed from several DNA elements including intergenic regions, promoters, and enhancers in eukaryotes [18] (Fig. 1). A variety of mechanisms are involved in the biogenesis of lncRNAs, including generation of mature ends by ribonuclease P (RNaseP) cleavage, creation of small nucleolar RNA (snoRNA), the formation of protein (snoRNP) complex caps at their ends, as well as creation of circular structures [19,20]. During biogenesis of lncRNAs, sub-nuclear structures, termed “paraspeckles”, are found in close proximity to specific lncRNAs [21]. Four specific proteins (PSPs) are required for paraspeckle formation [21,22]. The exact mechanism of synthesis and regulation of lncRNAs has yet to be detailed. Techniques, such as cross linking immunoprecipitation (CLIP), ChIRP-Seq (Chromatin Isolation via RNA purification), phylogenetic lineage tracing, RNA structure mapping, ribosome profiling, genetic screens, and genome engineering through CRISPR [23–25], are likely to help in this task.

3. IncRNAs and stroke

Long non-coding RNAs play a significant role in ischemic stroke. Numerous aberrantly expressed lncRNAs have been identified in ischemic stroke samples of human or animal models [26,27]. Among them, anti-sense non-coding RNA in INK4 locus (ANRIL), MALAT1, H19, N1LR, the maternally expressed gene 3 (MEG3), CaMK2D-associated transcript 1 (C2dat1), taurine up-regulated gene 1 (TUG1), small nucleolar RNA host gene 14 (SNHG14), and Fos downstream transcript (FosDT) were shown to affect angiogenesis, cell death, cell apoptosis, as well as inflammation in the course of ischemic stroke (Table 1, Fig. 2).

3.1. Angiogenesis

One of the first identified lncRNAs is MALAT1, which promotes cancer proliferation and metastasis via gene expression and alternative splicing [28–31]. MALAT1 is a stable and conserved lncRNA (~7 kb) [32], and is expressed in vascular endothelial cells, skeletal muscle, cardiomyocytes. MALAT1 thought to be involved in angiogenesis and pathological myogenesis [33–36]. In addition, high expression of MALAT1 is inherent to cell nucleus speckles, a pre-mRNA processing domain with a role in gene expression regulation or organization [37]. MALAT1 can also affect pre-mRNA splicing by interacting with splicing factors [38], and in cancers, MALAT1 expression is upregulated by HIF-1α or hypoxia [39,40].

In animal stroke models, such as middle cerebral artery occlusion (MCAO) and oxygen-glucose deprivation (OGD), MALAT1 expression is significantly increased (6.05-fold) [26]. MALAT1 knockout mouse leads to a larger size brain infarct, reduced sensorimotor function, and decreased neurological scores after MCAO [41]. Knockout of MALAT1 is also associated with reduced vascular growth mice retinas [42], consistent with studies on angiogenesis in experimental cancer models [42–44]. In the post-ischemic phase, cerebral vasculature has an important role in the recovery outcomes. Thus, increasing expression of MALAT1 in ischemic stroke affords protection. Further, MALAT1 knockout is characterized...
by increased expression of Bim, pro-apoptotic factor, pro-inflammatory cytokines, interleukin 6 (IL-6), E-selectin, as well as monocyte chemotactic protein-1 (MCP-1), both in ischemic murine brain and brain microvascular endothelial cells (BMECs) [41]. These findings suggest that MALAT1 has protective effect on cerebral ischemic injuries by inhibiting inflammation and endothelial cell death.

3.2. Inflammation

ANRIL, an anti-sense RNAs co-clustered with the p15/CDKN2B-p16/CDKN2A-p14/ARF locus in chromosome 9p21, is involved in cancers and cardiovascular diseases [45–47]. ANRIL has several splice variants with a length of ~3.9 kb [48]. In cancers, ANRIL activates by factor-1α and c-Myc which are hypoxia-inducible [49,50]. ANRIL can bind to PRC1/2 and mediates silence gene expression of INK4b-ARF-INK4a locus [51]. The enhanced expression of ANRIL is correlated with coronary artery disease, atherosclerosis, as well as stroke [52–55]. ANRIL expression, associated to variants of chromosome 9p21.3, has been suggested as a novel genetic marker for stroke [56]. Its expression is increased in rat cerebral infarcted cortex [57], resulting in activation of 1κB/NF-κB pathways and vascular-endothelial growth factor (VEGF)/-VEGF receptor 1 (FLT-1) [57], thus promoting inflammation and angiogenesis. Binding the VEGF to FLT-1 acts as a stimulus for fetal angiogenesis, as well as maintaining endothelial function in adult animals [58]. NF-κB dissociates from 1κB in stresses e.g. oxidative stress (OS), cytokines, ultra-violet irradiation, and viral or bacterial antigens. NF-κB translocates to the nucleus and modulates adaptive immune response genes [59]. By activating the VEGF/FLT-1 as well as 1κB/NF-κB pathways, ANRIL may significantly contribute to pro-inflammation and angiogenesis.

In addition, caspase recruitment domain (CARD) family member 8, referred to as TUCAN/CARDINAL, is another ANRIL target [60]. rs2043211, an SNP in CARD8 decreases CARD8 expression, and is associated with reduced risks of ischemic stroke [61]. Furthermore, increase or decrease in ANRIL stimulates or inhibits CARD8 expression in HepG2 cells, respectively [62]. ANRIL activation suppresses NF-κB by activating CARD8; therefore, likely inhibiting inflammation. Overall, the increased ANRIL levels enhance angiogenesis via VEGF/FLT-1 pathway, and regulate inflammation through NF-κB pathway in ischemic stroke.

3.3. Autophagy

LncRNA-H19 is a 2.3 kb conserved RNA coded by the H19 gene and expressed only in the maternal allele [63]. H19 control growth and development in the embryo [64]. At the first stage (6–8 weeks gestation) of embryonal development, both H19 alleles (paternal and maternal) are expressed. After 10-weeks of gestation, only the maternal H19 alleles are expressed [65]. By targeting another imprinted gene, Igf2, H19 can gain function in controlling the embryo’s growth [66]. The hypermethylation of the H19 promoter and methylation of the 3’ side of H19 in a specific allele is related to the change in H19 expression [65]. Indeed, in pathological conditions, for example, oxidative stress and cancer, the expression of H19 is upregulated [67–69]. H19 levels increased in stroke subjects compared to healthy subjects [70] affording diagnostic tool for ischemic stroke [70]. Up-regulation of H19 expression has been also been shown in OGD/reoxygenation in SH-SY5Y
cells and ischemia/reperfusion rat brain [71]. Variation in H19 alleles, such as rs217727, has been shown to increase ischemic stroke risk [71]. Additional investigations showed that inhibiting H19 protects SH-SY5Y cells from autophagy and cell death induced by OGD/R. The dual specificity phosphatase 5 (DUSP5)-ERK1/2 axis has a role in pro-autophagy impact on H19. DUSP5, a protein kinase phosphatase activated by mitogens, inhibits the ERK1/2 pathway and autophagy [71–73]. Increased levels of H19 suppress DUSP5, and therefore activate autophagy and ERK1/2.

3.4. Apoptosis

N1LR, is a lncRNA, located on chromosome 9, with 1.8 kb length; its sequence has overlap with 5′-UTR of Nck1 gene sequence. To date, only one study examined N1LR’s function [74]. N1LR is expressed in cerebral ischemia/reperfusion rat model [75]. Decreased N1LR expression affects infarct volume. Reduction of N1LR expression is inherent to N2a cells undergoing OGD/R. Upregulation of N1LR is associated with a reduction in OGD/R-induced apoptosis in N2a cells by inhibiting the p53 activation [75]. Analysis of the genome location as well as RACE assay has shown overlapping between the N1LR sequences with 5′-UTR of Nck1. The Nck1 gene encodes a protein that plays an important role in glucose tolerance, insulin signaling, and cellular remodeling. Nck1 is increases in the brain of ischemic rats. Furthermore, the genetic ablation of lncRNA-N1LR increases Nck1 expression. However, increasing of lncRNA-N1LR expression did not impact Nck1 expression [74,76].

FosDT, a 604nt lncRNA, also termed MRAK159688, has an overlapping sequence with the down-stream of Fos [77]. The expression of FosDT is up-regulated (about 13 folds compared to the control) in the acute period of MCAO after focal ischemia [78]. Increased FosDT expression is associated with neurological dysfunction and post-stroke brain damage. Suppressing FosDT causes a reduction in infarct volume and improved recovery of post ischemia motor function in comparison with controls [78]. Bio-informatics analyses has shown that FosDT and Fos are congenic on chromosome 6q31 in rats [78]. Fos rapidly increased after brain injury [79]. The correlation between increased Fos with increased FosDT suggests transcriptional and/or regulatory interactions between them. FosDT attaches to the chromatin modifying proteins (CMPs) including Sin3a as well as co-repressors of transcription factor REST (coREST). These proteins are co-repressors for the transcription factor repressor element-1 silencing transcription factor (REST) [80]. In fact, REST represses neuronal function such as synaptic transmission and neural differentiation [81]. Furthermore, REST forms a complex consisting of Sin3a (REST-coREST-Sin3a) as well as coREST in rats with transient focal ischemia. This complex inhibits the expression of downstream genes such as NF-κB2, GluR2 and N-methyl-D-aspartate 1 and increases ischemic brain damages [78].

4. MicroRNA biogenesis

MicroRNAs are short (~22-nucleotide) non-coding RNAs which silence gene expression post-transcriptionally. The first miRNA has been identified in Caenorhabditis elegans in 1993 [88]; but the regulatory function of miRNAs was first recognized in 2001 [89–91].
miRNA binds to the target mRNA degrades it or blocks translation [92]. RNA polymerase II (Pol II) the most of miRNA genes in the nucleus to primary miRNAs (pri-miRNAs). Next, capping, splicing and polyadenylation are carried out by pri-miRNAs [93]. Most of the miRNAs are transcribed from dedicated miRNA gene loci and only 30% of miRNAs are expressed from introns. A single pri-miRNA may produce one or several miRNAs.

Long pri-miRNA is cleaved via Micro-processor consisting of DRO-SHA, an RNase III enzyme, as well as the respective co-factor; namely, DiGeorge syndrome critical region 8 (DGCR8) [94,95]. Two RNase III domains have been identified in DROSHA; each domain processes one strand of the dsRNA to cleave almost 60–70-nucleotide hairpin-shaped precursor miRNAs (pre-miRNAs) [94–97]. Microprocessor identifies the single-stranded RNA (ssRNA)–stem junction along with distance from the terminal loop. Therefore, it cleaves dsRNA from the junction with the flanking ssRNA and pre-miRNAs in the shape of the hairpin produce with a 1 or 2 nucleotide overhang at the 3′ end (group I and II miRNAs, respectively) [98–101]. Though the core components of DROSHA as well as DGCR8 have been regarded as essential for nearly all miRNA biogenesis, and micro-processor activities may be re-constituted with the recombinant DGCR8 and DROSHA proteins in vitro [95,96],

A variety of factors play important roles in processing of pri-miRNA (more details are illustrated later). Pre-miRNAs are exported to the cytoplasm through exportin 5 (XPO5) [102–104]. In the cytoplasm, DICER1 (RNase III enzyme) further processes pre-miRNAs [105]. In addition, DICER1 attachment to the end of pre-miRNA and a-symmetrical cleavage of dsRNA stem. DICER1 cleavages near the terminal loop and creates a mature miRNA duplex; while, 2-nucleotide are over hanged in the 3′ end [106]. Hence, DICER1 correlates with the transactivation responsive RNA-binding protein (TRBP),TARBP2, for binding to dsRNA [107]. TRBP increases the DICER1 cleavage fidelity of pre-miRNAs in a structure-dependent manner. TRBP also changes the selection of guide-strand of miRNA by promotion the formation of isomiRNAs, which are one nucleotide longer than the usual miRNAs; but TRBP is not essential for processing of pre-miRNA by DICER1 [108,109]. Moreover, TRBP physically links DICER1 and Argonaute proteins, including AGO2, AGO1, AGO4 and AGO3 in order to involve in formation of a miRNA-induced silencing complex (miRISC) [107]. The guide strand of the miRNA through an Argonaute protein retains in the miRISC. Then miRNA guides the complex to target mRNAs and post-transcriptionally silence gene expression. Such a condition is found in cytoplasmic foci, processing bodies (P-bodies) induced by mRNA silencing; however, P-bodies are not essential for gene silencing mediated by miRNA [110–112].

5. MicroRNAs and stroke

Expression of miRNAs after stroke has an important role in the disease. For example, three miRNAs including miR-497, miRNA 21 and miR-99a have been shown to attenuate ischemic volumes and save the neuronal cells from apoptosis, preserving neurological functions [113–115]. In addition, overexpression of miR-let-7c-5p and miR-424 showed reduced activation of microglia in cerebral ischemia [116]. Up-regulation of miR-103, miR-103, miR-132 as well as miR-126 diminish neurobehavioral as well as neuropathological alterations in hemorrhagic stroke. These effects occur by protection of
BBB integrity, attenuating neuroinflammation and decreasing neuronal apoptosis [117–119]. Moreover, neurogenesis and angiogenesis in mouse brain is ameliorated by up-regulation of miR-210, promoting repair [120]. However, miRNA can also have a negative role. For instance, Liu et al. reported that miR-155 silencing increases migration, proliferation, and angiogenesis due to reduced cellular apoptosis, and production of reactive oxygen species (ROS) [121]. In agreement, in hemorrhagic stroke, miR-27b silencing has been shown to mitigate neurological loss by reducing cell death and repressing neuro-inflammation. Additionally, miR-124 and miR-155 have been shown to play a role in macrophage polarization [122]. Furthermore, miRNAs have an opposite effect in modulation of the synaptic plasticity. For example, miR-134 has been shown to improve the remodeling of neuronal structures through translational repression of Limk1-mRNA, a protein kinase with a role in dendritic spine development [123].

miR-212-5p is involved in ferroptotic neuronal death in traumatic brain injury (TBI) murine model. Overexpression of miR-212-5p attenuated ferroptosis while downregulation of miR-212-5p promoted ferroptotic cell death partially by targeting prostaglandin-endoperoxide synthase-2 in HT-22 and Neuro-2a cell lines. In addition, administration of miR-212-5p in controlled cortical impact mice significantly improved learning and spatial memory [124].

Compared with non-DM stroke mice, T2DM-stroke mice exhibit significantly decreased serum and brain tissue miR-126 expression. Endothelial cells and EC-Exo contain high levels of miR-126 compared with other cell types or exosomes derived from other types of cells, respectively (smooth muscle cells, astrocytes, and marrow stromal cells). EC-Exo treatment of T2DM-stroke mice significantly improves neurological and cognitive function, increases axon density, myelin density, vascular density, arterial diameter, as well as induces M2 macrophage polarization in the ischemic boundary zone [125].

5.1. Inflammation

Xie et al. reported on the ability of miR-181a to promote the cellular survival in vitro through repressing inflammation processes in macrophages as well as monocytes [126]. However, Moon has shown that miR-181a silencing attenuated neuronal apoptosis induced by forebrain ischemia [127].

Inflammation is an intricate response after injury and promotes repair process [128]. Enhanced immune responses may be detrimental [129], and can be an important determinant of stroke prognosis [117, 130–132]. Both hemorrhagic and ischemic stroke trigger microglial activation and inflammatory factors release, including TNF-α [133,134], promoting brain injury [135–137]. Moreover, T-lymphocytes, natural killer cells, polymorpho-nuclear leukocytes and mononuclear phagocytes produce and release several peripherally-derived cytokines which participate in neuroinflammation after stroke [138,139].

Numerous genes function to regulate neuroinflammation. These genes are targeted by miRNAs [140–142]. Lentiviral over-expression of miR-424 diminishes brain injuries following the ischemic stroke by repressing microglial activity [116]. miR-let-7c-5p has a
neuro-protective effect against neuroinflammation after ischemic stroke, preventing the translational repression of caspase-3 and microglia activation [143]. miR-124 is known as ‘brain-specific miRNA’ because it is expressed particularly in the central nervous system (CNS) [144,145]. Laterza et al. demonstrated that miR-124 is overexpressed in plasma following the brain injuries caused by MCAO [144]. Additionally, this microRNA suppressed the CCAAT/enhancer-binding protein alpha (C/EBP-α) and PU.1 directly as its down-stream element, resulting in microglia quiescence. Furthermore, miR-124 inhibited experimental autoimmune encephalomyelitis (EAE) by macrophage deactivation.

Toll-like receptors (TLRs) have been shown to have major functions in neuro-inflammation following stroke [146–148]. Zhang et al. reported that miR-181c inhibited expressing TLR4 via attachment to 3′ UTR of its gene, thus reducing levels of the nuclear factor kappa light chain enhancer of the activated B cells (NF-κB) as well as generation of the down-stream pro-inflammatory factors [149]. Furthermore, up-regulation of miR132 in mice hemorrhagic stroke leads to a better prognosis in comparison to controls. In addition, over-expression of miR132 represses activated microglia and pro-inflammatory cytokine production [119]. Yuan and colleagues in an experimental model of ICH have shown that miR-367 reduced IRAK4 levels by direct binding to its 3′-UTR. MiR-367 also inhibits NF-κB activation and synthesis of its downstream pro-inflammatory elements. Another study has shown that miR-223 improves the neurological functions by down-regulating NLRP3 as well as inflammation inhibition via caspase-1 and IL-1beta [150].

miRNAs have key roles in anti-inflammatory impact in brain due to the regulation of microglia and microphage polarization. MiR-155, by targeting M2-associated genes, promotes the M1 phenotype. Indeed, this microRNA targets different genes related to the M2 phenotype that mitigate production of M2-induced proinflammatory factors such as IL13Rα1, CD206 and IL-10 and Arg-1 [151,152].

5.2. Apoptosis

Apoptosis is energy-dependent and also known as programmed cell death [153]. Apoptosis has a key role in physiological metabolism, growth, and development. [154,155]. However, uncontrolled apoptosis may lead to different disorders such as cancers, Alzheimer’s disease as well as stroke [156,157]. Apoptosis is triggered by either internal or external pathways. External pathways occur surface death receptors activation. These receptors include Fas and TNF-related apoptosis like tumor necrosis factor (TNF)-α and ligand receptors, whereas interior pathways are associated with mitochondrial signaling pathways [158, 159]. Following stroke, a mass influx of Ca\(^{2+}\) into the cell is triggered, resulting in apoptosis-inducing factor (AIF) release or mitochondrial cytochrome c (Cytc) [160]. Binding Cytc to the apoptotic protease-activating factor-1 as well as procaspase-9 forms an apoptosome, in turn activating caspase-9. Eventually, caspase-3 leads to damages to nDNA as well as the ensuing cell death. In addition, AIF translocates to the nucleus, causing a large-scale (50 kb) DNA-fragmentation and cell death mediated by caspase activation [161].

miRNAs regulate post-stroke neuronal survival through regulation of the level of target genes [162,163]. miR-298 has been overexpressed in blood and brain specimens in experimental models of cerebral ischemia as well as ICH models [164]. An anti-apoptotic
factor is miR-21. Buller et al. studied the levels of miR-21 expression both in vivo and in vitro. Levels of this microRNA increased following ischemic stroke secondary to decreased Fas ligand (FasL) G, a cell death-inducing ligand [115]. MiR-155 is responsible for regulating cellular apoptosis via modulation of caspase-3 expression. Knocking down miR-155 decreased apoptosis in brain microvessel endothelial cells [121]. Moreover, miR-99a has been shown to prevent pro-caspase-3 activation and caspase-3 expression and decreased neuronal apoptosis following ischemic stroke. In addition, miR-99a mitigated neuronal injury after the cerebral Ischemia/Reperfusion (I/R), via cell cycle as well as the cellular apoptosis regulation. This suggests miR-99a as a novel treatment factor targeting neuronal cell cycle re-entry after ischemic stroke [114]. Additionally, the bcl-2 family contributes to apoptosis modulation. MiR-106b-5p, miR-181a, miR-497, miR-384-5p and miR134 increase apoptosis by reducing the levels of bcl-2 proteins [113,126,127,165,166].

MiR-132 has been shown to reduce neuronal mortality in ICH mice, following hemorrhagic stroke. Ip-regulation of miR-132 caused decreased likelihood of neurological deficits [119]. Lentivirus induced up-regulation of miR-126 was shown to be protective in ICH by triggering anti-apoptotic mediators secondary to reduced levels of caspase-3 [118]. Increased miR-103-3p expression in an experimental model of the sub-arachnoid hemorrhage associated with decreased levels of caveolin-1 has also been shown [167].

5.3. Oxidative stress

OS contributes to the pathogenesis of many disorders. It represents over-balance of pro-oxidants (ROS/RNS) and or deficiencies in the antioxidant systems in the cells [168–170]. Hence, free-radicals as well as ROS generation in the course of the stroke cause N-methyl-D-aspartic acid (NMDA) glutamate receptors [171], mitochondrial impairment, exceeding Ca\(^{2+}\) [172–174], and activation of neuronal nitric oxide synthase (nNOS) [175]. Detoxifying enzymes and antioxidants include superoxide dismutase (SOD), glutathione reductase, glutathione-S-transferase and glutathione peroxidase, which sustain redox homeostasis [176,177]. Erythroid-2-related factor-2 (Nrf2) plays a neuroprotective role against brain damage after stroke, hydrogen peroxide (H\(_2\)O\(_2\)) exposure, glutamate excitotoxicity and Ca\(^{2+}\) overload [178].

miRNAs modulate Nrf2 mRNA levels [179]. Following ischemic stroke, miR-93 suppresses Nrf2 and homeoxygenease-1 (HO-1) [180]. During cerebral ischemia, miR-424 reduces infarct volume by decreasing ROS levels in cortex and elevating manganese SOD (MnSOD) and extra-cellular SOD. miR-424 has also been shown to decrease H\(_2\)O\(_2\) induced injuries in the neuronal cultures, by increasing cell viability as well as MnSOD activities, and decrease levels of lactate dehydrogenase leakage and malondialdehyde [181]. Moreover, miR-23a-3p and miR-106b-5p may have a neuro-protective impact against the post-ischemic oxidative injuries via overexpressing MnSOD [182,183]. Additionally, miR-145 suppresses SOD2 following ischemic stroke [184]. Xu et al. reported suppression of miR-27b reduces brain injury and results in overexpression of Hmox1, Nrf2, Nqo1 as well as SOD1-following ICH through Nrf2/ARE pathway [185]. Nonetheless, few investigations focused on the antioxidative activity of miRNAs in the hemorrhagic stroke. More studies are needed to investigate the contribution of the miRNAs in the hemorrhagic stroke.

Biomed Pharmacother. Author manuscript; available in PMC 2021 August 01.
5.4. Angiogenesis

Zhang et al. explored structural modifications following stroke, reporting increased vascular volumes from 3% to 6% at 90th days after stroke [186]. Angiogenesis regulator miRNAs is a possible therapeutic target in ischemic stroke [187]. MiR-210 has a significant function in angiogenesis following cerebral ischemia, partially by increasing vascular endothelial growth factor (VEGF) expression. In vitro, under hypoxic conditions, miR-210 mediates tube formation and migration of vascular endothelial cells [120]. Ma and colleagues reported that in a rat model of ICH, miR-129-5p represses the HMGB1-RAGE signaling pathway and consequently re-vascularization [188]. Up-regulation of miR126 is protective against ICH, increasing angiogenesis by elevating VEGF-A protein levels [160]. Hence, improved angiogenesis may represent a therapeutic modality for stroke through the pharmacological regulation of miRNAs.

Neurotrophic agents, representing small polypeptide molecules, have a key part in cell differentiation, proliferation, development and migration of the nervous system. Earlier investigations indicated that neurotrophic agents such as brain derived neurotrophic factor (BDNF), nerve growth factor, ciliary neurotrophic factor, insulin-like growth factor-1 (IGF-1) and glial-derived neurotrophic factor mitigate neuronal death as well as the brain lesions [189,190].

miR-Let7f has been shown in an experimental model of cerebral ischemia to support IGF-1-like neuroprotection [190]. Additionally, suppression of miR-134 diminishes ischemic damages by promoting Bcl-2as well as BDNF expression. Moreover, miR-30-5p and miR-107 modulates BDNF expression [191]. In addition, neural precursor cells (NPCs) and endogenous neural stem cells (NSCs) can be switched on and migrate toward the injured location[192]. In this regard, miR-21 can modulate NPC’s activity via Wnt and transforming growth factor (TGF)-β signaling pathways. Furthermore, miR-34a modulates NPC proliferation negatively following cerebral ischemia [193]. Based on studies in type-2 diabetic mice following stroke, miR-126 may also promote the neuro-restorative function induced with umbilical cord blood cells [194]. Table 1 and Fig. 3 listed different miRNAs involved in stroke pathogenesis (Table 2).

6. Exosome biogenesis

Exosomes are largely conserved amongst eukaryotic organisms [207]. Exosomes originate via an endocytic route, and they are generated by the inward budding of plasma membranes [208].

Exosomes can be derived from stem cells isolated from different cell sources such as mesenchymal stem cells, endothelial progenitor cells, and fibroblasts. The mesenchymal stem cells (MSCs) are the most commonly used on research which have usually been isolated from synovium, bone marrow, and adipose tissue. The three major categories of extracellular vesicles are (a) apoptotic bodies, (b) microparticles or microvesicles, and (c) exosomes or nanovesicles [209].
Exosomes consist of the conserved proteins such as CD63 (membrane-related proteins like LAMP-3), CD9, Alix, CD81, as well as tumor susceptibility gene 101 protein [210], and the tissue- or cell-type-specific proteins, which indicate their cellular sources [211]. Sphingomyelin, ceramide and cholesterol are used to enrich exosome membranes [212]. On the other hand, exosomes consist of several biologically active molecules like proteins, deoxyribonucleic acids, ribonucleic acids (RNAs), microRNAs (miRs) and lipids [213]. Exosomal miRs or exosomal engineered miRs function in regulating the progression of various diseases, such as cancers, cardiovascular disease, and stroke [214–216].

Exosomal intercellular communications are mediated by bio-active molecules and are capable of targeting certain types of cells and modifying their target cell functions by delivering lipids, nucleic acids and proteins [217]. The majority of proteins in exosomes derive from the parent cell membranes, Golgi and the cytosol but seldom from endoplasmic reticulum or mitochondria [207]. Hence, cytosolic proteins will remain in exosomes and the ones derived from the plasma membranes will be kept in the vesicle membrane and maintain a similar topology of the cells with the potent contribution to sequestering the soluble ligands [218].

Exosomal proteins have a role in the antigen presentation, cell structure and motility as well as cell adhesion. Moreover, they modulate stress and contribute to transcription, protein synthesis, membrane fusion and trafficking [219]. Several functional impacts of exosomes could be ascribed to RNA and miR content transfer [217]. miRs and RNAs have been proposed as the most related cargo in the exosomes with regard to their abilities of a little number of molecules for influencing diverse proteins or enzymes in 1 or more cellular pathways in the targeted cells [220].

7. Exosomal microRNAs and stroke

The ever-increasing information suggested the involvement of the exosome-mediated intercellular communication in the brain re-modeling via transfer of the cargo from the source cells to the targeted cells (Fig. 4) [221]. It is possible to isolate the exosomes from bio-fluids such as CSF and from the supernatant of the cells that have been cultured in the exosome-free medium via centrifugation and the other procedures [222]. Exosomes are commonly enriched with tetra-spanin proteins (CD81 & CD63), the regulator of the endosomal trafficking Alix, as well as chaperone protein HSP70, though exosomes’ volume is variable according to the cell origin and pathological and physiological conditions [222, 223]. Analyses of the proteomic and RNA analyses also showed that exosomes are the carriers of cargoes of proteins, RNAs and lipids such as miRNAs and mRNAs [222, 223]. Nonetheless, there is insufficient information on the loading of biological substances into the individual exosomes. In fact, each brain cell releases exosomes [222, 224, 225]. In comparison to exosomes separated from the wild type mice brains, exosomes from brains of transgenic mice overexpress human amyloid-β (Aβ) precursor protein (APP) [224]. In addition, the full-length APP cleavage via β-secretase takes place into the endosomes that is one of the fractions of Aβ peptides sorted for multi-vesicular bodies, and release of such Aβ peptides is seen in conjunction with exosomes [226]. Furthermore, exosomes isolated from the prefrontal cortices of the cases suffering from schizophrenia and bi-polar disorder indicated
diverse profiles of the exosomal miRNAs in comparison to the exosomes from control brains [225]. Collectively, these studies suggest that exosomes released by both human and mouse brains under disease conditions change profiles of exosomal cargo proteins and miRNAs and that exosomes enriched with neurotoxic C-terminal fragments of APP may contribute to the spread of Aβ peptides to the brain. Even though in vivo investigations could not specify the cellular source of the exosomes, information obtained from cultured cells suggested that exosomes released by neurons as well as the astrocytes consist of Aβ peptides [226,227].

The ever-increasing information also demonstrated miRNAs are the essential modulators in ICH [228,229]. Exosomal miRNAs expression has a wide variance in diverse types of cells and pathological states, and thus miR-modified exosome can change its functions. In addition, analyses have shown the high conservation of MiR-146a-5p amongst the mice, rats and humans. Other investigations also referred to the abundance of miR-146a-5p in the MSCs, and stimulatory impact of the humans’ umbilical cord MSC-exosome on the primordial follicles is applied by carrying the functional miR-146a-5p [230,231]. Accordingly, there can be an association between the advantageous functions of exosome and the increased levels of miR-146a-5p it carries. A number of investigations revealed that miR-146a protects against diverse brain impairment [232–234]. Moreover, it contributes to the regulation of microglia or macrophages in the ischemic stroke [235]. Additionally, miR-146a-5p downregulates in the ICH cases’ sera [236] and protects against ICH via suppressing TRAF6/NF-κB pathway [234]. Nonetheless, particular mechanism of miR-146a-5p in neuro-protection following the ICH should be highlighted.

Duan et al. addressed the impact of the exosome derived from the miR-146a-5p enriched bone-marrow mesenchymal stem-cells (BMSCs-miR-146a-5p-Exos) on the experimental ICH [237]. Analysis showed the induction of ICH in adult male Sprague-Dawley rats by intra-striatally injecting the collagenase type IV. Researchers verified binding miR-146a-5p and the respective target genes through the luciferase reporter assay. BMSCs-miR-146a-5p-Exos injection ameliorated the neurological functions, diminished degenerative and apoptotic neurons, and suppressed the inflammatory responses. Results also revealed the clear inhibition of M1 polarization of micro-glia after ICH in the rats by the miR-146a-5p enriched Exosome that has been followed by lower expression of the proinflammatory mediators released via M1 microglia-like monocyte chemo attractant protein-1 (MCP-1), the inducible nitric oxide synthase (iNOS), as well as cyclooxygenase-2 (COX-2). Consequently, direct targeting of interleukin-1 receptor--associated kinase1 (IRAK1) as well as nuclear factor of the activated T-cells 5 (NFAT5) has been shown by miR-146a-5p involved in inflammation responses and polarization of M1 microglia or macrophages. miR-146a-5p riched BMSCs-Exos afforded neuroprotection and functional improvement after ICH via reduction of neuronal apoptosis as well as inflammation related to suppression of the microglial M1 polarization via down-regulating IRAK1 and NFAT5expression [237].

Endogenous neural stem-cells of the adults’ brains have been largely found in the subventricular zone (SVZ) area of lateral ventricle and sub-granular zone (SGZ) region of hippocampus [238,239]. Neural stem-cells are be activated following stroke and subsequently migrate into the lesioned areas and differentiate into the functional neural cells [240,241].
Exosomes from the peri-ischemic striatum and determined them through exosomal bio-markers so that the differentially expressed miRNAs have been detected with micro-array chip. In the next step, they cultured the primary stem cells and utilized OGD as well as reperfusion (OGD/R) for mimic vitro ischemic injuries. Analysis has shown the greater level of the exosomal bio-markers of CD81 and TSG101 in the peri-ischemic striatum following the EA treatment that displayed 25 differentially expressed miRNAs in the isolated exosomes, of which miR-146b has been chosen for additional analyses. Furthermore, EA enhanced the miR-146b expression and its suppressors have been capable of blocking the impacts. Researchers also approved that EA up-regulated miR-146b expression for promoting the differentiation of the neural stem cells into the neurons in the peri-ischemic striatum. According to the results, OGD/R delayed differentiating the neural stem-cells and thus miR-146b suppressors repressed its differentiation. Moreover, NeuroD1 showed its contribution to the differentiation of the neural stem cells into neurons. Additionally, in vivo experiments showed that EA enhanced differentiating the NeuroD1-mediated neural stem cells through miR-146b and ability of EA for improving the neurological deficiencies via miR-146b following the ischemic stroke. Finally, EA promoted differentiating the endogenous neural stem-cells through the exosomal miR-146b for improving the neurological injuries following the ischemic stroke [242].

miRNA-126 affords its neuro-protective effects against the ischemia injuries by regulating the genes expression like phosphor-inositide-3-kinase regulatory sub-unit 2 (PIK3R2). Moreover, the vascular cell adhesion molecule 1 (VCAM-1) in ECs [243,244]. VCAM-1 as well as PIK3R2 have a relationship to the resistance against endothelial dysfunction and vascular inflammation that have been proposed as the 2 prominent procedures correlated to the neuronal damages of reperfusion or ischemia [245]. Lower activation of the inflammatory pathways and endothelial dysfunctions must contribute to the RIPC-mediated neuro-protection through the exosomal miRNA-126 [246]. Chemical reagents such as DNMT inhibitors involve in the neuro-protection in the rodents that suffer from mild ischemia [247,248]. Pandi et al. [249] revealed that small interfering RNA (siRNA)-mediated DNMT3A knockdown decreased infarction in vivo as well as PC12-cell death in vitro. It is noteworthy that there is no information on the mechanisms involved in neuro-protection. Hu et al.[250]found that lower expression of DNMT may result in the greater expression level of a number of genes such as metallothionein because of hypo-methylation, protecting neuronal cells from the hypoxia damages or ischemia. Notably, DNMT3A andDNMT1 partially increased in SH-SY5Y cells that over-expressed miRNA-126 in our research. Consequently, a number of compensatory mechanisms possibly exist amongst DNMT3A, DNMT3B and DNMT1 so that one of them is lost or remarkably diminished [251].

Another investigation explored if exosomal miRNA-126 from RIPC serum may have neuro-protective role [252]. Researchers isolated the exosomes from the venous serum of 4 healthy-young male cases prior to and following RIPC. Consequently, the level of DNMT and DNMT3B activities has been down-regulated in the SH-SY5Y cells that have been incubated with the RIPC exosomes. Following the miRNA-126 over-expression in the SH-SY5Y cells, the overall methylation level as well as DNMT3B gene expression have been down-regulated in the above cells that has been compatible with the bio-informatics
prediction. Finally, RIPC exosomes are capable of influencing the cell-cycle and increasing the tolerance of OGD in the SH-SY5Y cells and apparently RIPC has neuro-protective effects by down-regulating DNMTs expression in the neural cells via upregulating the serum exosomal miRNA-126 [252]. Table 3 lists exosomal miRNAs that are involved in stroke.

8. Exosomal long non-coding RNAs and stroke

Researchers showed the lncRNAs in exosomes [265]. Exosomal lncRNAs have shown as the attractive bio-markers for stroke and there is insufficient information on the contribution of exosomal lncRNAs to stroke pathogenesis.

Acute minor stroke (AMS) has been introduced as a sort of hypoxic ischemic necrosis with at least four National Institutes of Health Stroke Scale (NIHSS) score. Nonetheless, initial diagnosis of the AMS is difficult due to the absence of efficient molecular markers. Thus, experts in the field tended to reveal several long non-coding RNAs (lncRNAs) related to AMS.

Xu et al. examined potent bio-markers of lncRNAs in the exosomes isolated from the blood serum of AMS cases for initial detection of the disease [266]. For this reason, they utilized RNA-seq, GO enrichment and KEGG pathway analyses as well as RT-qPCR for validating the level of expression of 4 of 11 differentially expressed lncRNAs (lnc-NTRK3–4, lnc-CRKL-2, lnc-CALM1–7 & RPS6KA2-AS1) that contribute to neuro-trophin signaling pathways. Moreover, expression level of lnc-NTRK3–4 and lnc-CRKL-2 considerably enhanced the cases suffering from AMS whereas level of expression of RPS6KA2-AS1 and lnc-CALM1–7 remarkably diminished. In conclusion, these newly revealed lncRNAs may be used as novel joint biomarkers for the early detection of AMS [266].

Chen et al. addressed modifications in the miRNAs and lncRNAs expression patterns in exosomes derived from the vascular endothelial cells upon heat stroke [267]. Analyses identified 10 considerably up-regulated and 10 down-regulated lncRNAs in exosomes derived from the heat stroke temperature treated cells. Consequently, KEGG (Kyoto Encyclopedia of Genes & Genomes) and GO (Gene Ontology) have been utilized for evaluating the signaling pathways of differential expression in lncRNAs. Interaction network of the lncRNAs-miRNAs-mRNA with ceRNA (competing endogenous RNA) principle revealed that the identified miRNAs and lncRNAs in the endothelial cell exosomes may be utilized as the noninvasive bio-markers for the heat strokes [267].

9. Conclusion

A variety of internal and external factors are associated with initiation and progression of stroke. Epigenetic regulations play essential tasks in the stroke pathogenesis. LncRNAs and miRNAs act as epigenetic regulators which are involved in the modulation of several biological mechanisms such as angiogenesis, growth, and differentiation. Several studies revealed that these molecules have critical roles in various stages of stroke. LncRNAs and miRNAs, as main regulators, have therapeutic, diagnostic and prognostic potential in the brain diseases including stroke. Circulating ncRNAs which have cell type- and tissue-specific expression patterns and remarkable stability in peripheral blood have also been
studied to detect patients at risk for incident or recurrent stroke, and to predict stroke outcome. Moreover, exosomes have been regarded as the new materials with the prominent inter-cellular roles in the mediation of neuro-restorative events following strokes and neural injuries. Advancement in exosome therapy would benefit from, 1. Identifying cellular signals through which ischemic brain can influence quantity as well as volume of exosomes released by the brain parenchymal cells and remote organs, 2. Getting information of the influence of exosomal cargo on expressing the endogenous genes and proteins in the recipient cells of the damaged brains, 3. Delineating particular kinds of cells targeted by the brain parenchymal cell–derived exosomes, and 4. Deciphering the impacts of gender, comorbidity and age on cellular production of exosomes and the respective cargo as well as the impact of comorbidity, age and gender in responding to the exosome treatments after strokes. However, other investigations on exosomes as tools of inter-cellular communication in ischemic brain should provide in valuable information on the contribution of exosomes to stroke pathogenesis and exosomal therapy.

**Funding**

The present study was funded by a grant from the Vice Chancellor for Research, Kashan University of Medical Sciences, in Iran. MA was supported in part by grants from the National Institute of Environmental Health Sciences (NIEHS) R01ES07331 and R01ES10563.

**Abbreviations:**

- **AGO**: Argonaute
- **AIF**: apoptosis-inducing factor
- **ANRIL**: antisense non-coding RNA in the INK4 locus
- **APAF-1**: Apoptotic protease activating factor-1
- **Arg-1**: Arginase 1
- **Arl2**: ADP Ribosylation Factor Like GTPase 2
- **BBB**: blood-brain barrier
- **Bcl-2**: B-cell lymphoma 2
- **BDNF**: brain-derived neurotrophic factor
- **BMECs**: brain microvascular endothelial cells
- **BMF**: BCL-2 modifying factor
- **CaMKIIδ**: Ca(2+)/calmodulin-dependent protein kinase II delta
- **CARD**: Caspase recruitment domain family member
- **CD**: Cluster of Differentiation
- **C2dat1**: CaMK2D-associated transcript 1
| Abbreviation | Full Form |
|--------------|-----------|
| CDKN2A       | Cyclin Dependent Kinase Inhibitor 2A |
| CDKN2B       | Cyclin Dependent Kinase Inhibitor 2B |
| C/EBP-α      | CCAAT/enhancer-binding protein alpha |
| ChIRP-Seq    | Chromatin Isolation by RNA purification |
| CLIP         | crosslinking immunoprecipitation |
| CMPs         | chromatin-modifying proteins |
| coREST       | co-repressors of the transcription factor REST |
| CRISPR       | clustered regularly interspaced short palindromic repeats |
| Cytc         | cytochrome c |
| DGCR8        | DiGeorge syndrome critical region 8 |
| dsRNA        | Double-strand RNA |
| DUSP5        | Dual specificity phosphatase 5 |
| EAE          | experimental autoimmune encephalomyelitis |
| ERK          | extracellular signal-regulated kinase |
| FasL         | Fas ligand |
| FLT-1        | Fms-like tyrosine kinase 1 |
| FosDT        | Fos downstream transcript |
| GluR2        | glutamate receptor 2 |
| GPx1         | Glutathione Peroxidase 1 |
| HIF-1α       | Hypoxia-inducible factor 1-alpha |
| HMGB1        | high mobility group box 1 protein |
| HO-1         | hemeoxygenase-1 |
| H2O2         | hydrogen peroxide |
| ICH          | Intracerebral hemorrhage |
| IGF-1        | insulin-like growth factor-1 |
| Igf2         | Insulin Like Growth Factor 2 |
| IL13Rα1      | Interleukin 13 receptor, alpha 1 |
| I/R          | Ischemia/Reperfusion |
| IL           | interleukin |
| Acronym   | Full Name                                                                 |
|-----------|---------------------------------------------------------------------------|
| IRAK4     | interleukin-1 receptor-associated kinase 4                                |
| Limk1     | LIM Domain Kinase 1                                                      |
| IncRNAs   | long non-coding RNAs                                                     |
| MALAT1    | Metastasis Associated Lung Adenocarcinoma Transcript 1                   |
| MCAO      | middle cerebral artery occlusion                                          |
| MCP-1     | monocyte chemotactic protein-1                                            |
| MEG3      | maternally expressed gene 3                                               |
| miRISC    | miRNA-induced silencing complex                                           |
| miRNAs    | microRNAs                                                                |
| MnSOD     | manganese SOD                                                            |
| Nck1      | non-catalytic region of tyrosine kinase adaptor protein 1                |
| ncRNAs    | Non-coding RNAs                                                          |
| NCX       | sodium-calcium exchanger                                                 |
| N2a       | Neuro2a                                                                  |
| NF-κB     | nuclear factor kappa-light-chain-enhancer of activated B cells           |
| NLRP3     | NOD-, LRR- and pyrin domain-containing protein 3                         |
| NMDA      | N-methyl-D-aspartic acid                                                  |
| nNOS      | nitric oxide synthase                                                    |
| NOX4      | NADPH Oxidase 4                                                          |
| NPCs      | neural precursor cells                                                   |
| Nqo1      | NAD(P)H Quinone Dehydrogenase 1                                          |
| Nrf2      | nuclear factor namely erythroid-2-related factor-2                       |
| NSCs      | neural stem cells                                                        |
| OGD       | oxygen-glucose deprivation                                               |
| OGD/R     | Oxygen-glucose deprivation and reperfusion                              |
| P-bodies  | processing bodies                                                        |
| PI3K      | Phosphoinositide 3-kinases                                               |
| PKN2      | Protein Kinase N2                                                        |
| Abbreviation | Definition |
|--------------|------------|
| Pol II       | polymerase II |
| PRC1/2       | polycomb repressive complex 1 and 2 |
| pre-miRNAs   | precursor miRNAs |
| pri-miRNAs   | primary miRNAs |
| RACE         | Rapid Amplification of cDNA Ends |
| RAGE         | Receptor for advanced glycation end products |
| REST         | repressor element-1 silencing transcription factor |
| RhoB         | Ras Homolog Family Member B |
| RNAi         | RNA interference |
| RNase P      | ribonuclease P |
| RNA-seq      | RNA sequencing |
| RNS          | Reactive nitrogen species |
| ROS          | reactive oxygen species |
| RUNX-1       | Runt-related transcription factor 1 |
| SHIP1        | SH-2 containing inositol 5’ polyphosphatase 1 |
| SNHG14       | small nucleolar RNA host gene 14 |
| snoRNA       | small nucleolar RNA |
| snoRNP       | small nucleolar ribonucleoprotein |
| SNP          | single nucleotide polymorphism |
| SOD          | superoxide dismutase |
| ssRNA        | single-stranded RNA |
| TGF          | transforming growth factor |
| TLRs         | Toll-like receptors |
| TNF-α        | Tumor necrosis factor alpha |
| TRBP         | transactivation-responsive RNA-binding protein |
| TUG1         | Taurine Up-Regulated 1 |
| Txnrd2       | Thioredoxin Reductase 2 |
| VCAM-1       | vascular cell adhesion molecule 1 |
| VEGF         | vascular endothelial growth factor |
VILIP-1 Visinin like protein 1
WHO World Health Organization
XIAP X-linked inhibitor of apoptosis protein
XPO5 exportin 5

References

[1]. W.H. Organization, The World Health Report: 2004: Changing History, 2004.
[2]. Banerjee TK, Roy MK, Bhoi KK, Is stroke increasing in India–preventive measures that need to be implemented, J. Indian Med. Assoc 103 (3) (2005) 162, 164, 166 passim. [PubMed: 16173293]
[3]. He W, Wei D, Cai S, Chen Li, S, Chen W, Altered long non-coding RNA transcriptomic profiles in ischemic stroke, Hum. Gene Ther 29 (6) (2018) 719–732. [PubMed: 29284304]
[4]. Jolana L, Kamli D, The role of microRNA in ischemic and hemorrhagic stroke, Curr. Drug Deliv 14 (6) (2017) 816–831. [PubMed: 27691978]
[5]. Mirzaei H, Momeni F, Saadatpour L, Sahebkar A, Goodarzi M, Masoudifar A, Kouhpayeh S, Salehi H, Mirzaei HR, Jafari MR, MicroRNA: relevance to stroke diagnosis, prognosis, and therapy, J. Cell Physiol 233 (2) (2018) 856–865. [PubMed: 28067403]
[6]. Mirzaei H, Stroke in women: risk factors and clinical biomarkers, J. Cell Biochem 118 (12) (2017) 4191–4202. [PubMed: 28498508]
[7]. Borges FT, Reis LA, Schor N, Extracellular vesicles: structure, function, and potential clinical uses in renal diseases, Braz. J. Med. Biol. Res 46 (10) (2013) 824–830. [PubMed: 24141609]
[8]. Blandford SN, Galloway DA, Moore CS, The roles of extracellular vesicle microRNAs in the central nervous system, Glia 66 (11) (2018) 2267–2278. [PubMed: 29726599]
[9]. Barile L, Vassalli G, Exosomes: Therapy delivery tools and biomarkers of diseases, Pharmacol. Ther 174 (2017) 63–78. [PubMed: 28202367]
[10]. Soria FN, Pampliega O, Bourdenx M, Meissner WG, Bezdj E., Dehay B, Exosomes, an unmasked culprit in neurodegenerative diseases, Front. Neurosci 11 (2017) 26. [PubMed: 28197068]
[11]. Schmitz SU, Grote P, Herrmann BG, Mechanisms of long noncoding RNA function in development and disease, Cell. Mol. Life Sci 73 (13) (2016) 2491–2509. [PubMed: 27007508]
[12]. Delas MJ, Hannon GJ, IncRNAs in development and disease: from functions to mechanisms. 2017. 7(7).
[13]. Akerman I, Tu Z, Beucher A, Rolando D, Sauty-Colace C, Benazra M, Nakic N, Yang J, Wang H, Pasquali L, Moran I, Garcia-Hurtado J, Castro N, Gonzalez-Franco R, Stewart AF, Bonner C, Piemonti L, Berney T, Grop L, Kerr-Conte J, Pattou F, Argmann C, Schadt E, Ravassard P, Ferrer J, Human pancreatic β cell IncRNAs control cell-specific regulatory networks, Cell Metab. 25 (2) (2017) 400–411. [PubMed: 28041957]
[14]. Morán I, Akerman I, van de Bunt M, Xie R, Benazra M, Nammo T, Arnes L, Nakić N, García-Hurtado J, Rodriguez-Segui S, Pasquali L, Sauty-Colace C, Beucher A, Scharffmann R, van Arensbergen J, Johnson PR, Berry A, Lee C, Harkins T, Gmyr V, Pattou F, Kerr-Conte J, Piemonti L, Berney T, Hanley N, Gloyan AL, Sussel L, Langman L, Brayman KL., Sander M, McCarthy MI, Ravassard P, Ferrer J, Human β cell transcriptome analysis uncovers IncRNAs that are tissue-specific, dynamically regulated, and abnormally expressed in type 2 diabetes, Cell Metab. 16 (4) (2012) 435–448. [PubMed: 23040067]
[15]. Vafadar A, Shabaninejad Z, Movahedpour A, Mohammadi S, Fatollahzadeh S, Mirzaei HR, Namdar A, Savardashtaki A, Mirzaei H, Long non-coding RNAs as epigenetic regulators in cancer, Curr. Pharm. Des 25 (33) (2019) 3563–3577. [PubMed: 31470781]
[16]. Hashemipour M, Boroumand H, Mollazadeh S, Tajiknia V, Nouroollahzadeh Z, Rohani Borj M, Pourghadamyari H, Rahimian N, Hamblin MR, Mirzaei H, Exosomal microRNAs and exosomal long non-coding RNAs in gynecologic cancers, Gynecol. Oncol 161 (1) (2021) 314–327. [PubMed: 33581845]
[17]. Rahimian N, Razavi ZS, Aslanbei gi F, Mirkhbabaz AM, Piroozmand H, Shahrzad MK, Hamblin MR, Mirzaei H, Non-coding RNAs related to angiogenesis in gynecological cancer, Gynecol. Oncol. 2021.

[18]. Wu H, Yang L, Chen L-L, The diversity of long noncoding RNAs and their generation, Trends Genet. 33 (8) (2017) 540–552. [PubMed: 28629949]

[19]. Vicens Q, Westhof E, Biogenesis of circular RNAs, Cell 159 (1) (2014) 13–14. [PubMed: 25259915]

[20]. Dahariya S, Paddibhatla I, Kumar S, Raghuvanshi S, Pallepati A, Gup ti RK, Long non-coding RNA: Classification, biogenesis and functions in blood cells, Mol. Immunol 112 (2019) 82–92. [PubMed: 31079005]

[21]. Naganuma T, Hirose T, Paraspeckle formation during the biogenesis of long non-coding RNAs, RNA Biol. 10 (3) (2013) 456–461. [PubMed: 23324609]

[22]. Yamazaki T, Hirose T, The building process of the functional paraspeckle with long non-coding RNAs, Front. Biosci. (Elite Ed.) 7 (2015) 1–41. [PubMed: 25553361]

[23]. Yoon JH, Gorospe M, Cross-linking immunoprecipitation and qPCR (CLIP-qPCR) analysis to map interactions between long noncoding RNAs and RNA-binding proteins, Methods Mol. Biol. 1402 (2016) 11–17. [PubMed: 26721479]

[24]. Salehi S, Taheri MN, Azarpira N, Zare A, Behzad-Behbahani A, State of the art technologies to explore long non-coding RNAs in cancer, J. Cell. Mol. Med. 21 (12) (2017) 3120–3140. [PubMed: 28631377]

[25]. Li JH, Liu S, Zheng LL, Wu J, Sun WJ, Wang ZL, Zhou H, Qu LH, Yang JH, Discovery of protein-lncRNA interactions by integrating large-scale CLIP-Seq and RNA-Seq datasets, Front. Bioeng. Biotechnol 2 (2014) 88. [PubMed: 25642422]

[26]. Zhang J, Yuan L, Zhang X, Hamblin MH, Zhu T, Meng F, Li Y, Chen YE, Yin KJ, Altered long non-coding RNA transcriptomic profiles in brain microvascular endothelium after cerebral ischemia, Exp. Neur ol 277 (2016) 162–170. [PubMed: 26746985]

[27]. Dykstra-Aiello C, Jickling GC, Ander BP, Shroff N, Zhan X, Liu D, Hull H, Orantia M, Stamova BS, Sharp FR, Altered expression of long noncoding RNAs in blood after ischemic stroke and proximity to putative stroke risk loci, Stroke 47 (12) (2016) 2896–2903. [PubMed: 27834745]

[28]. Ji P, Diederichs S, Wang W, Böing S, Schneider PM, Tidow N, Brandt B, Buerger H, Bulk E, Thomas M, Berdel WE, Serve H, Müller-Tidow C, MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer, Oncogene 22 (39) (2003) 8031–8041. [PubMed: 12970751]

[29]. Yoshimoto R, Mayeda A, Yoshida M, Nakagawa S, MALAT1 long non-coding RNA in cancer, Biochim. Biophys. Acta 1859 (1) (2016) 192–199. [PubMed: 26434412]

[30]. Guffanti A, Iacono M, Pelucchi P, Kim N, Soldà G, Croft LJ, Taft RJ, Rizzi E, Askarian-Amiri M, Bonnal RJ, Callari M, Mignone F, Pesole G, Bertalot G, Bernardi LR, Albertini A, Lee C, Mattick JS, Zucchi I, De Bellis G, A transcriptional sketch of a primary human breast cancer by 454 deep sequencing, BMC Genom. 10 (2009) 163.

[31]. Chou J, Wang B, Zheng T, Li X, Zheng L, Hu J, Zhang Y, Xing Y, Xi T, MALAT1 induced migration and invasion of human breast cancer cells by competitively binding miR-1 with cdc42, Biochem. Biophys. Res. Commun 472 (1) (2016) 262–269. [PubMed: 26926567]

[32]. Ip JY, Nakagawa S, Long non-coding RNAs in nuclear bodies, Dev. Growth Differ 54 (1) (2012) 44–54. [PubMed: 22070123]

[33]. Zhao J, Li L, Peng L, MAPK1 up-regulates the expression of MALAT1 to promote the proliferation of cardiomyocytes through PI3K/AKT signaling pathway, Int. J. Clin. Exp. Pathol 8 (12) (2015) 15947–15953. [PubMed: 26884868]

[34]. Watts R, Johnsen VL, Shearer J, Hittel DS, Myostatin-induced inhibition of the long noncoding RNA Malat1 is associated with decreased myogenes is, Am. J. Physiol. Cell Physiol 304 (10) (2013) C995–C1001. [PubMed: 23485710]

[35]. Tang Y, Jin X, Xiang Y, Chen Y, Shen CX, Zhang YC, Li YG, The lncRNA MALAT1 protects the endothelium against ox-LDL-induced dysfunction via upregulating the expression of the miR-22-3p target genes CXCR2 and AKT, FEBS Lett. 589 (20 Pt B) (2015) 3189–3196. [PubMed: 26364720]
[36]. Michalik KM, You X, Manavski Y, Doddaballapur A, Zörnig M, Braun T, John D, Ponomareva Y, Chen W, Uchida S, Boon RA, Dimmeler S. Long noncoding RNA MALAT1 regulates endothelial cell function and vessel growth, Circ. Res 114 (9) (2014) 1389–1397. [PubMed: 24602777]

[37]. Hutchinson JN, Ensminger AW, Clemson CM, Lynch CR, Lawrence JB, Chess A. A screen for nuclear transcripts identifies two linked noncoding RNAs associated with SC35 splicing domains, BMC Genom. 8 (2007) 39.

[38]. Sun W, Yang Y, Xu C, Guo J. Regulatory mechanisms of long noncoding RNAs on gene expression in cancers, Cancer Genet. 216–217 (2017) 105–110.

[39]. Yuan P, Cao W, Zhang Q, Li G, Guo X, Fan J. The HIF-2alpha-MALAT1-miR-216b axis regulates multi-drug resistance of hepatocellular carcinoma cells via modulating autophagy, Biochem. Biophys. Res. Commun 478 (3) (2016) 1067–1073. [PubMed: 27524242]

[40]. Sallé-Lefort S, Miard S, Nolin MA, Boivin L, Paré MÈ, Debigaré R, Picard F. Hypoxia upregulates Malat1 expression through a CaMKK/AMPK/HIF-1alpha axis, Int. J. Oncol 49 (4) (2016) 1731–1736. [PubMed: 27499160]

[41]. Zhang X, Tang X, Liu K, Hamblin MH, Yin KJ. Long noncoding RNA malat1 regulates cerebrovascular pathologies in ischemic, Stroke 37 (7) (2017) 1797–1806.

[42]. Michalik KM, You X, Manavski Y, Doddaballapur A, Zörnig M, Braun T, John D, Ponomareva Y, Chen W, Uchida S, Boon RA, Dimmeler S. Long noncoding RNA MALAT1 regulates endothelial cell function and vessel growth, Circ. Res 114 (9) (2014) 1389–1397. [PubMed: 24602777]

[43]. Tee AE, Liu B, Song R, Li J, Pasquier E, Cheung BB, Jiang C, Marshall GM, Haber M, Norris MD, Fletcher JJ, Dinger ME, Liu T. The long noncoding RNA MALAT1 promotes tumor-driven angiogenesis by up-regulating pro-angiogenic gene expression, Oncotarget 7 (8) (2016) 8663–8675. [PubMed: 26848616]

[44]. Nduom EK, Wei J, Yaghi NK, Huang N, Kong LY, Gabrusiewicz K, Ling X, Zhou S, Ivan C, Chen JQ, Burks JK, Fuller GN, Calin GA, Conrad CA, Creasy C, Ritthipichai K, Radvanyi L, Heimberger AB, PD-L1 expression and prognostic impact in glioblastoma, Neuro Oncol. 18 (2) (2016) 195–205. [PubMed: 26326309]

[45]. Shete S, Hosking FJ, Robertson LD, Dobbins SE, Sanson M, Malmer B, Simon M, Marie Y, Boisselier B, Delattre JY, Hoang-Xuan K, El Hallani S, Idéhiai A, Zelenika D, Andersson U, Henriksson R, Bergenheim AT, Feychting M, Lönn S, Ahlbom A, Schramm J, Linnebank M, Hemminki K, Kumar R, Hepworth SJ, Price A, Armstrong G, Liu Y, Gu X, Yu R, Lau C, Schoemaker M, Muir K, Swerdlow A, Lathrop M, Bondy M, Houlston RS. Genome-wide association study identifies five susceptibility loci for glioma, Nat. Genet 41 (8) (2009) 899–904. [PubMed: 19578367]

[46]. McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, Cox DR, Hinds DA, Pennacchio LA, Tybjaerg-Hansen A, Folsom AR, Boerwinkle E, Hohns HH, Cohen JC. A common allele on chromosome 9 associated with coronary heart disease, Science 316 (5830) (2007) 1488–1491. [PubMed: 17478681]

[47]. Pasmant E, Laurendeau I, Héron D, Vidaud M, Vidaud D, Bièche I. Characterization of a germ-line deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense noncoding RNA whose expression clusters with ARF, Cancer Res. 67 (8) (2007) 3963–3969. [PubMed: 17440112]

[48]. Folkersens L, Kyriakou T, Goel A, Peden J, Målarstig A, Paulsson-Berne G, Hamsten A, Hugh W, Franco-Cereceda A, Gabrielsen A, Eriksson P, c PROCARDIS, Relationship between CAD risk genotype in the chromosome 9p21 locus and gene expression. Identification of eight new ANRIL splice variants, PLoS One 4 (11) (2009) 7677.

[49]. Lu Y, Zhou X, Xu L, Rong C, Shen C, Bian W. Long noncoding RNA ANRIL could be transactivated by c-Myc and promote tumor progression of non-small-cell lung cancer, Onco Targets Ther. 9 (2016) 3077–3084. [PubMed: 27307748]

[50]. Wei X, Wang C, Ma C, Sun W, Li H, Cai Z. Long noncoding RNA ANRIL is activated by hypoxia-inducible factor-1α and promotes osteosarcoma cell invasion and suppresses cell apoptosis upon hypoxia, Cancer Cell Int. 16 (2016) 73. [PubMed: 27688736]
[51]. Aguilo F, Zhou MM, Walsh MJ, Long noncoding RNA, polycomb, and the ghosts haunting INK4b-ARF-INK4a expression, Cancer Res. 71 (16) (2011) 5365–5369. [PubMed: 21828241]

[52]. Holdt LM, Beutner F, Scholz M, Gielen S, Gäbel G, Bargert H, Schuler G, Thierry J, Teupser D, ANRIL expression is associated with atherosclerosis risk at chromosome 9p21, Arterioscler. Thromb. Vasc. Biol. 30 (3) (2010) 620–627. [PubMed: 20056914]

[53]. Consortium P, Deloukas P, Kanoni S, Willenborg C, Farrall M, Assimes TL, Thompson JR, Ingelsson E, Saleheen D, Erdmann J, Goldstein BA, Stirrup K, König IR, Hager J, Hallmans G, Han BG, Hunt SE, Kang HM, Illig T, Kessler T, Knowles JW, Kolovou G, Kuusisto J, Langenberg C, Langford C, Leander K, Lokki ML, Lundmark A, McCarthy MI, Meisinger C, Melander O, Mihailov E, Maouche S, Morris AD, Müller-Nurasyid M, MutHER C, Nikus K, Peden JF, Rayner NW, Rasheed A, Rosinger S, Rubin D, Rumpf MP, Schäfer A, Sivananthan M, Song C, Stewart AF, Tan ST, Thorgeirsson G, van der Schoot CE, Wagner PJ, Wellcome Trust Case Control, Wells GA, Wild PS, Yang TP, Amouyel P, Arveiler D, Basart H, Boehnke M, Boerwinkle E, Brambilla P, Cambien F, Cupples AL, de Faire U, Deghhan A, Diemert P, Epstein SE, Evans A, Ferrario MM, Ferrières J, Gauguier D, Go AS, Goodall AH, Lupoli M, de Faire U, Gudnason V, Hazen SL, Holm H, Iribarren C, Jang J, Kähönen M, Kee F, Keavney B, Chromosome 9p21 SNPs associated with multiple disease phenotypes correlate with ANRIL expression, PLoS Genet. 6 (4) (2010), 1000899.

[54]. Cunnington MS, Santibanez Koref M, Mayosi BM, Burn J, Keavney B, Chromosome 9p21 SNPs associated with multiple disease phenotypes correlate with ANRIL expression, PLoS Genet. 6 (4) (2010), 1000899.

[55]. Amouyel P, From genes to stroke subtypes, Lancet Neurol. 11 (11) (2012) 931–933. [PubMed: 23041236]

[56]. Zhang W, Chen Y, Liu P, Chen J, Song L, Tang Y, Wang Y, Liu J, Hu FB, Hui R, Variants on chromosome 9p21.3 correlated with ANRIL expression contribute to stroke risk and recurrence in a large prospective stroke population, Stroke 43 (1) (2012) 14–21. [PubMed: 22034006]

[57]. Zhang B, Wang D, Ji TF, Shi L, Yu JL, Overexpression of IncRNA ANRIL up-regulates VEGF expression and promotes angiogenesis of diabetes mellitus combined with cerebral infarction by activating NF-kappaB signaling pathway in a rat model, Oncotarget 8 (10) (2017) 17347–17359. [PubMed: 28060742]

[58]. Cao Y, Positive and negative modulation of angiogenesis by VEGFR1 ligands, Sci. Signal 2 (59) (2009) 1.

[59]. Smith EM, Gregg M, Hashemi F, Schott L, Hughes TK, Corticotropic Releasing Factor (CRF) activation of NF-kappaB-directed transcription in leukocytes, Cell Mol. Neurobiol 26 (4–6) (2006) 1021–1036. [PubMed: 16633893]

[60]. Stilo R, Leonardi A, Formisano L, Di Jeso B, Vito P, Liguoro D, TUCAN/CARDINAL and DRAL participate in a common pathway for modulation of NF-kappaB activation, FEBS Lett. 521 (1–3) (2002) 165–169. [PubMed: 12067710]

[61]. Ben Hamad M, Cornelis F, Marzouk S, Chaibchoug B, Bahliou Z, Rebai A, Fakhfah F, Ayadi H, Petit-Teixeira E, Malaef A, Association study of CARD8 (p.C10X) and NLRP3 (p.Q705K) variants with rheumatoid arthritis in French and Tunisian populations, Int. J. Immunogenet 39 (2) (2012) 131–136. [PubMed: 22128899]

[62]. Bai Y, Nie S, Jiang G, Zhou Y, Zhou M, Zhao Y, Li S, Wang F, Lv Q, Huang Y, Yang Q, Li Q, Li Y, Xia Y, Liu Y, Liu J, Qian J, Li B, Wu G, Wu Y, Wang B, Cheng X, Yang Y, Ke T, Li H, Ren X, Ma X, Liao Y, Xu C, Tu X, Wang QK, Regulation of CARD8 expression by ANRIL and
association of CARD8 single nucleotide polymorphism rs2043211 (p.C10X) with ischemic stroke, Stroke 45 (2) (2014) 383–388. [PubMed: 24385277]

[63]. Brunkow ME, Tilghman SM, Ectopic expression of the H19 gene in mice causes prenatal lethality, Genes Dev. 5 (6) (1991) 1092–1101. [PubMed: 2044956]

[64]. Gaboria A, Jammes H, Dandolo L, The H19 locus: role of an imprinted non-coding RNA in growth and development, Bioessays 32 (6) (2010) 473–480. [PubMed: 20486133]

[65]. Jinno Y, Ikeda Y, Yun K, Maw M, Masuzaki H, Fukuda H, Inuzuka K, Fujishita A, Ohtani Y, Okimoto T, Establishment of functional imprinting of the H19 gene in human developing placenta, Nat. Genet 10 (3) (1995) 318–324. [PubMed: 7670470]

[66]. Wilkin F, Paquette J, Ledru E, Hamelin C, Pollak M, Deal CL, H19 sense and antisense transgenes modify insulin-like growth factor-II mRNA levels, Eur. J. Biochem 267 (13) (2000) 4020–4027. [PubMed: 10866801]

[67]. Wang WT, Ye H, Wei PP, Han BW, He B, Chen ZH, Chen YQ, LncRNAs H19 and HULC, activated by oxidative stress, promote cell migration and invasion in cholangiocarcinoma through a ceRNA manner, J. Hematol. Oncol 9 (1) (2016) 117. [PubMed: 27809873]

[68]. Matouk II, Raveh E, Abu-lail R, Mezan S, Gilon M, Gershtain E, Birman T, Gallula J, Schneider T, Barkali M, Richler C, Fellig Y, Sorin V, Hubert A, Hochberg A, Czerniak A, Oncofetal H19 RNA promotes tumor metastasis, Biochim. Biophys. Acta 1843 (7) (2014) 1414–1426. [PubMed: 24703882]

[69]. Matouk II, DeGroot N, Mezan S, Ayesh S, Abu-lail R, Hochberg A, Galun E, The H19 non-coding RNA is essential for human tumor growth, PLoS One 2 (9) (2007) 845.

[70]. Wang J, Zhao H, Fan Z, Li G, Ma Q, Tao Z, Wang R, Feng J, Luo Y, Long noncoding RNA H19 promotes neuroinflammation in ischemic stroke by driving histone deacetylase 1-dependent M1 microglial polarization, Stroke 48 (8) (2017) 2211–2221. [PubMed: 28630232]

[71]. Wang J, Cao B, Han D, Sun M, Feng J, Long non-coding RNA H19 induces cerebral ischemia reperfusion injury via activation of autophagy, Aging Dis. 8 (1) (2017) 71–84. [PubMed: 28203482]

[72]. Han W, Fu X, Xie J, Meng Z, Gu Y, Wang X, Li L, Pan H, Huang W, MiR-26a enhances autophagy to protect against ethanol-induced acute liver injury, J. Mol. Med 93 (9) (2015) 1045–1055. [PubMed: 25877859]

[73]. Tao H, Cao W, Yang JJ, Shi KH, Zhou X, Liu LP, Li J, Long noncoding RNA H19 controls DUSP5/ERK1/2 axis in cardiac fibroblast proliferation and fibrosis, Cardiovasc. Pathol 25 (5) (2016) 381–389. [PubMed: 27318893]

[74]. Wu Z, et al., Erratum to: LncRNA-N1LR enhances neuroprotection against ischemic stroke probably by inhibiting p53 phosphorylation, Mol. Neurobiol (2017) 7686–7688. [PubMed: 28054233]

[75]. Wu Z, Wu P, Zuo X, Yu N, Qin Y, Xu Q, He S, Cen B, Liao W, Ji A, LncRNA-N1LR enhances neuroprotection against ischemic stroke probably by inhibiting p53 phosphorylation, Mol. Neurobiol 54 (10) (2017) 7670–7685. [PubMed: 27844279]

[76]. Wu Z, Wu P, Zuo X, Yu N, Qin Y, Xu Q, He S, Cen B, Liao W, Ji A, LncRNA-N1LR enhances neuroprotection against ischemic stroke probably by inhibiting p53 phosphorylation, Mol. Neurobiol 54 (10) (2017) 7670–7685. [PubMed: 27844279]

[77]. Ji Y, Guo X, Zhang Z, Huang Z, Zhu J, Chen QH, Gui L, CaMKIIδ mediates phenylephrine induced cardiomyocyte hypertrophy through store-operated Ca2+ entry, Cardiovasc. Pathol 27 (2017) 9–17. [PubMed: 27940402]

[78]. Mehta SL, Kim T, Vemuganti R, Long noncoding RNA FoxDT promotes ischemic brain injury by interacting with REST-associated chromatin-modifying proteins, J. Neurosci 35 (50) (2015) 16443–16449. [PubMed: 26674869]

[79]. Shimazu M, Mizushima H, Sasaki K, Arai Y, Matsumoto K, Shioida S, Nakai Y, Expression of c-fos in the rat cerebral cortex after focal ischemia and reperfusion, Brain Res. Bull 33 (6) (1994) 689–697. [PubMed: 8193923]

[80]. Dharap A, Pokrzywa C, Vemuganti R, Increased binding of stroke-induced long non-coding RNAs to the transcriptional corepressors Sin3A and coREST, ASN Neuro 5 (4) (2013) 283–289. [PubMed: 24063527]
[81]. Paonessa F, Criscuolo S, Sacchetti S, Amoroso D, Scarongella H, Pecoraro Bisogni F, Carminati E, Pruzzo G, Maraglino L, Cesca F, Benfenati F. Regulation of neural gene transcription by optogenetic inhibition of the RE1-silencing transcription factor, Proc. Natl. Acad. Sci. USA 113 (1) (2016) E91–E100. [PubMed: 26699507]

[82]. Ren W, Yang X. Pathophysiology of long non-coding RNAs in ischemic stroke, Front. Mol. Neurosci 11 (2018) 96. [PubMed: 29651234]

[83]. Wang Y, Mo Y, Gong Z, Yang X, Zhang M, Zhang S, Xiong F, Xiang B, Zhou M, Liao Q, Zhang W, Li X, Li X, Li Y, Li G, Zeng Z, Xiong W. Circular RNAs in human cancer, Mol. Cancer 16 (1) (2017) 25. [PubMed: 28143578]

[84]. Wang J, Cao B, Han D, Sun M, Feng J. Long non-coding RNA H19 induces cerebral ischemia reperfusion injury via activation of autophagy, Aging Dis. 8 (1) (2017) 71–84. [PubMed: 28203482]

[85]. Chen S, Wang M, Yang H, Mao L, He Q, Jin H, Ye ZM, Luo XY, Xia YP, Hu B. LncRNA TUG1 sponges microRNA-9 to promote neurons apoptosis by up-regulated Bcl2II1 under ischemia, Biochem. Biophys. Res. Commun 485 (1) (2017) 167–173. [PubMed: 28202414]

[86]. Xu Q, Deng F, Xing Z, Wu Z, Cen B, Xu S, Zhao Z, Nepomuceno R, Bhuiyan MI, Sun D, Wang QJ, Ji A. Long non-coding RNA C2dat1 regulates CaMKII expression to promote neuronal survival through the NF-κB signaling pathway following cerebral ischemia, Cell Death Dis. 7 (3) (2016) 2173.

[87]. Zhang B, Wang D, Ji TF, Shi L, Yu JL. Overexpression of IncRNA ANRIL up-regulates VEGF expression and promotes angiogenesis of diabetes mellitus combined with cerebral infarction by activating NF-κB signaling pathway in a rat model, Oncotarget 8 (10) (2017) 17347–17359. [PubMed: 28060742]

[88]. Lee RC, Feinbaum RL, Ambros V. C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14, Cell 75 (5) (1993) 843–854. [PubMed: 8252621]

[89]. Lee RC, Ambros V. An extensive class of small RNAs in Caenorhabditis elegans, Science 294 (5543) (2001) 862–864. [PubMed: 11679672]

[90]. Lau NC, Lim LP, Weinstein EG, Bartel DP. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans, Science 294 (5543) (2001) 858–862. [PubMed: 11679671]

[91]. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs, Science 294 (5543) (2001) 853–858. [PubMed: 11679670]

[92]. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of posttranscriptional regulation by microRNAs: are the answers in sight? Nat. Rev. Genet 9 (2) (2008) 102–114. [PubMed: 18197166]

[93]. Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, Kim VN. MicroRNA genes are transcribed by RNA polymerase II, EMBO J. 23 (20) (2004) 4051–4060. [PubMed: 15372072]

[94]. Denli AM, Tops BB, Plasterk RH, Ketting RF, Hannon GJ. Processing of primary microRNAs by the Microprocessor complex, Nature 432 (7014) (2004) 231–235. [PubMed: 15531879]

[95]. Gregory RI, Yan KP, Amuthan G, Chendrimada T, Doratotaj B, Cooch N, Shiekhattar R. The Microprocessor complex mediates the genesis of microRNAs, Nature 432 (7014) (2004) 235–240. [PubMed: 15531877]

[96]. Han J, Lee Y, Yeom KH, Kim YK, Jin H, Kim VN. The Drosha-DGCR8 complex in primary microRNA processing, Genes Dev. 18 (24) (2004) 3016–3027. [PubMed: 15574589]

[97]. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P, Rádmark O, Kim S, Kim VN. The nuclear RNase III Drosha initiates microRNA processing, Nature 425 (6956) (2003) 415–419. [PubMed: 14508493]

[98]. Heo I, Ha M, Lim J, Yoon MJ, Park JE, Kwon SC, Chang H, Kim VN. Monouridylation of premicroRNA as a key step in the biogenesis of group II let-7 microRNAs, Cell 151 (3) (2012) 521–532. [PubMed: 23063654]

[99]. Burke JM, Kelenis DP, Kincaid RP, Sullivan CS. A central role for the primary microRNA stem in guiding the position and efficiency of Drosha processing of a viral pri-miRNA, RNA 20 (7) (2014) 1068–1077. [PubMed: 24854622]
[100]. Zeng Y, Yi R, Cullen BR, Recognition and cleavage of primary microRNA precursors by the nuclear processing enzyme Drosha, EMBO J. 24 (1) (2005) 138–148. [PubMed: 15565168]

[101]. Han J, Lee Y, Yeom KH, Nam JW, Heo I, Rhee JK, Sohn SY, Cho Y, Zhang BT, Kim VN, Molecular basis for the recognition of primary microRNAs by the Drosha-DGCR8 complex, Cell 125 (5) (2006) 887–901. [PubMed: 16751099]

[102]. Bohnsack MT, Czapinski K, Görlich D, Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs, RNA 10 (2) (2004) 185–191. [PubMed: 14730017]

[103]. Lund E, Güttinger S, Calado A, Dahlberg JE, Kutay U, Nuclear export of microRNA precursors, Science 303 (5654) (2004) 95–98. [PubMed: 14631048]

[104]. Yi R, Qin Y, Macara IG, Cullen BR, Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs, Genes Dev. 17 (24) (2003) 3011–3016. [PubMed: 14681208]

[105]. Park J-E, Heo I, Tian Y, Simanshu DK, Chang H, Lee D, Patel DJ, Kim VN, Dicer recognizes the 5′ end of RNA for efficient and accurate processing, Nature 475 (7355) (2011) 201–205. [PubMed: 21753850]

[106]. Bernstein E, Caudy AA, Hammond SM, Hannon GJ, Role for a bidentate ribonuclease in the initiation step of RNA interference, Nature 409 (6818) (2001) 363–366. [PubMed: 11201747]

[107]. Chendrimada TP, Gregory RI, Kumaraswamy E, Norman J, Cooch N, Nishikura K, Shiekhattar R, TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing, Nature 436 (7051) (2005) 740–744. [PubMed: 15973356]

[108]. Kim Y, Yeo J, Lee JH, Cho J, Seo D, Kim JS, Kim VN, Deletion of human tarbp2 reveals cellular microRNA targets and cell-cycle function of TRBP, Cell Rep. 9 (3) (2014) 1061–1074. [PubMed: 25437560]

[109]. Lee HY, Doudna JA, TRBP alters human microprocessor precursor RNA processing in vitro, RNA 18 (11) (2012) 2012–2019. [PubMed: 23006623]

[110]. Eulalio A, Behm-Ansmant I, Schweizer D, Izaurralde E, P-body formation is a consequence, not the cause, of RNA-mediated gene silencing, Mol. Cell. Biol 27 (11) (2007) 3970–3981. [PubMed: 17403906]

[111]. Liu J, Valencia-Sanchez MA, Hannon GJ, Parker R, MicroRNA-dependent localization of targeted mRNAs to mammalian P-bodies, Nat. Cell Biol 7 (7) (2005) 719–723. [PubMed: 15937477]

[112]. Gregory RI, Chendrimada TP, Cooch N, Shiekhattar R, Human RISC couples microRNA biogenesis and posttranscriptional gene silencing, Cell 123 (4) (2005) 631–640. [PubMed: 16271387]

[113]. Yin K-J, Deng Z, Huang H, Hamblin M, Xie C, Zhang J, Chen YE, miR-497 regulates neuronal death in mouse brain after transient focal cerebral ischemia, Neurobiol. Dis 38 (1) (2010) 17–26. [PubMed: 20053374]

[114]. Tao Z, Zhao H, Wang R, Liu P, Yan F, Zhang C, Ji X, Luo Y, Neuroprotective effect of microRNA-99a against focal cerebral ischemia–reperfusion injury in mice, J. Neurol. Sci 355 (1–2) (2015) 113–119. [PubMed: 26055311]

[115]. Buller B, Liu X, Wang X, Zhang RL, Zhang L, Hozeska-Solgot A, Chopp M, Zhang ZG, MicroRNA-21 protects neurons from ischemic death, FEBS J. 277 (20) (2010) 4299–4307. [PubMed: 20840605]

[116]. Zhao H, Wang J, Gao L, Wang R, Liu X, Gao Z, Tao Z, Xu C, Song J, Ji X, Luo Y, MiRNA-424 protects against permanent focal cerebral ischemia injury in mice involving suppressing microglia activation, Stroke 44 (6) (2013) 1706–1713. [PubMed: 23613494]

[117]. Yuan B, Shen H, Lin L, Su T, Zhong L, Yang Z, MicroRNA367 negatively regulates the inflammatory response of microglia by targeting IRAK4 in intracerebral hemorrhage, J. Neuroinflamm 12 (1) (2015) 206.

[118]. Kong F, Zhou J, Zhou W, Guo Y, Li G, Yang L, Protective role of microRNA-126 in intracerebral hemorrhage, Mol. Med. Rep 15 (3) (2017) 1419–1425. [PubMed: 28112373]

[119]. Zhang Y, Han B, He Y, Li D, Ma X, Liu Q, Hao J, MicroRNA-132 attenuates neurobehavioral and neuropathological changes associated with intracerebral hemorrhage in mice, Neurochem. Int 107 (2017) 182–190. [PubMed: 27940326]
[120]. Zeng L, He X, Wang Y, Tang Y, Zheng C, Cai H, Liu J, Wang Y, Fu Y, Yang GY. MicroRNA-210 overexpression induces angiogenesis and neurogenesis in the normal adult mouse brain, Gene Ther. 21 (1) (2014) 37–43. [PubMed: 24152581]

[121]. Liu Y, Pan Q, Zhao Y, He C, Bi K, Chen Y, Zhao B, Chen Y, Ma X. MicroRNA-155 regulates ROS production, NO generation, apoptosis and multiple functions of human brain microvessel endothelial cells under physiological and pathological conditions, J. Cell. Biochem 116 (12) (2015) 2870–2881. [PubMed: 26012521]

[122]. Yin M, Chen Z, Ouyang Y, Zhang H, Wan Z, Wang H, Wu W, Yin X. Thrombin-induced, TNFR-dependent miR-181c downregulation promotes MLL1 and NF-κB target gene expression in human microglia, J. Neuroinflamm 14 (1) (2017) 132.

[123]. Schratz GM, Tuebing F, Nigh EA, Kane CG, Sabatini ME, Kiebler M, Greenberg ME. A brain-specific microRNA regulates dendritic spine development, Nature 439 (7074) (2006) 283–289. [PubMed: 16421561]

[124]. Xiao X, Jiang Y, Liang W, Wang Y, Cao S, Yan H, Gao L, Zhang L. miR-212-5p attenuates ferroptotic neuronal death after traumatic brain injury by targeting Ptgs2, Mol. Brain 12 (1) (2019) 78. [PubMed: 31533781]

[125]. Venkat P, Cui C, Chopp M, Zacharek A, Wang F, Landschoot-Ward J, Shen Y, Chen J. MiR-126 mediates brain endothelial cell exosome treatment–induced neurorestorative effects after stroke in type 2 diabetes mellitus mice, Stroke 50 (10) (2019) 2865–2874. [PubMed: 31394992]

[126]. Xie W, Li M, Xu N, Lv Q, Huang N, He J, Zhang Y. MiR-181a regulates inflammation responses in monocytes and macrophages, PLoS One 8 (3) (2013) 58639.

[127]. Moon J.-m, Xu L, Giffard RG. Inhibition of microRNA-181 reduces forebrain ischemia-induced neuronal loss, J. Cereb. Blood Flow Metab 33 (12) (2013) 1976–1982. [PubMed: 24002437]

[128]. Turrin NP, Rivest S. Molecular and cellular immune mediators of neuroprotection, Mol. Neurobiol 34 (3) (2006) 221–242. [PubMed: 17308354]

[129]. Brown GC, Neher JJ. Inflammatory neurodegeneration and mechanisms of microglial killing of neurons, Mol. Neurobiol 41 (2–3) (2010) 242–247. [PubMed: 20195798]

[130]. Brown GC, Neher JJ. Inflammatory neurodegeneration and mechanisms of microglial killing of neurons, Mol. Neurobiol 41 (2–3) (2010) 242–247. [PubMed: 20195798]

[131]. Bazzoni F, et al. Induction and regulatory function of miR-9 in human monocytes and neutrophils exposed to proinflammatory signals, Proc. Natl. Acad. Sci. USA 106 (13) (2009) 5282–5287. [PubMed: 19289835]

[132]. Amantea D, Nappi G, Bernardi G, Bagetta G, Corasaniti MT. Post-ischemic brain damage: pathophysiology and role of inflammatory mediators, FEBS J. 276 (1) (2009) 13–26. [PubMed: 19087196]

[133]. Brown GC, Neher JJ. Inflammatory neurodegeneration and mechanisms of microglial killing of neurons, Mol. Neurobiol 41 (2–3) (2010) 242–247. [PubMed: 20195798]

[134]. Eikelenboom P, Rozemuller AJ, Hoozemans JJ, Veerhuis R, van Gool WA. Neuroinflammation and Alzheimer disease: clinical and therapeutic implications, Alzheimer Dis. Assoc. Disord 14 (1) (2000) S54–S61. [PubMed: 10850731]

[135]. Mrak RE, Griffin WST. Glia and their cytokines in progression of neurodegeneration, Neurobiol. Aging 26 (3) (2005) 349–354. [PubMed: 15639313]

[136]. Cong F, Zhang JW, Li RF, Wang ZX, Wang WJ, Wang W. Unique roles of gold nanoparticles in drug delivery, targeting and imaging applications, Molecules 22 (9) (2017) 1445.

[137]. Bache S, Rasmussen R, Rossing M, Laigaard FP, Nielsen FC, Møller K. MicroRNA changes in cerebrospinal fluid after subarachnoid hemorrhage, Stroke 48 (9) (2017) 2391–2398. [PubMed: 28768799]

[138]. Ferrarese C, Mascarucci P, Zoia C, Cavarretta R, Frigo M, Begni B, Sarinella F, Frattola L, De Simoni MG. Increased cytokine release from peripheral blood cells after acute stroke, J. Cereb. Blood Flow. Metab 19 (9) (1999) 1004–1009. [PubMed: 10478652]
[140]. Guo D, Liu J, Wang W, Hao F, Sun X, Wu X, Bu P, Zhang Y, Liu Y, Liu F, Zhang Q, Jiang F, Alteration in abundance and compartmentalization of inflammation-related miRNAs in plasma after intracerebral hemorrhage, Stroke 44 (6) (2013) 1739–1742. [PubMed: 23559260]

[141]. Tan JR, Kaur P, Liu F, Armugam A, Wong PT, Jeyaseelan K, Koo YX, microRNAs in stroke pathogenesis, Curr. Mol. Med 11 (2) (2011) 76–92. [PubMed: 21342133]

[142]. Saugstad JA, MicroRNAs as effectors of brain function with roles in ischemia and injury, neuroprotection, and neurodegeneration, J. Cereb. Blood Flow. Metab 30 (9) (2010) 1564–1576. [PubMed: 20606686]

[143]. Ni J, Wang X, Chen S, Liu H, Wang Y, Xu X, Cheng J, Jia J, Zhen X, MicroRNA let-7c-5p protects against cerebral ischemia injury via mechanisms involving the inhibition of microglia activation, Brain Behav. Immun 49 (2015) 75–85. [PubMed: 25934573]

[144]. Laterza OF, Lim L, Garrett-Engele PW, Vlasakova K, Muniappa N, Tanaka WK, Johnson JM, Sina JF, Fare TL, Sistare FD, Glaab WE, Plasma MicroRNAs as sensitive and specific biomarkers of tissue injury, Clin. Chem 55 (11) (2009) 1977–1983. [PubMed: 19745058]

[145]. Meza-Sosa KF, Pedraza-Alva G, Pérez-Martínez L, microRNAs: key triggers of neuronal cell fate, Front. Cell. Neurosci 8 (2014) 175. [PubMed: 25009466]

[146]. Kariö K, Ni H, Capodici J, Lambhier M, Weissman D, mRNA is an endogenous ligand for Toll-like receptor 3, J. Biol. Chem 279 (13) (2004) 12542–12550. [PubMed: 14729660]

[147]. Kawai T, Akira S, The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors, Nat. Immunol 11 (5) (2010) 373–384. [PubMed: 20404851]

[148]. Weinstein JR, Koerner IP, Möller T, Microglia in ischemic brain injury, Fut. Neurol 5 (2) (2010) 227–246.

[149]. Zhang L, Li YJ, Wu XY, Hong Z, Wei WS, Micro RNA-181c negatively regulates the inflammatory response in oxygen-glucose-deprived microglia by targeting Toll-like receptor 4, J. Neurochem 132 (6) (2015) 713–723. [PubMed: 25545945]

[150]. Yang Z, Zhong L, Xian R, Yuan B, MicroRNA-223 regulates inflammation and brain injury via feedback to NLRP3 inflammasome after intracerebral hemorrhage, Mol. Immunol 65 (2) (2015) 267–276. [PubMed: 25710917]

[151]. Ruffell D, et al., A CREB-C/EBPβ cascade induces M2 macrophage-specific gene expression and promotes muscle injury repair, Proc. Natl. Acad. Sci. USA 106 (41) (2009) 17475–17480. [PubMed: 19805133]

[152]. Martinez-Nunez RT, Louafi F, Sanchez-Elsner T, The interleukin 13 (IL-13) pathway in human macrophages is modulated by microRNA-155 via direct targeting of interleukin 13 receptor α1 (IL13Ra1), J. Biol. Chem 286 (3) (2011) 1786–1794. [PubMed: 21097505]

[153]. Elmore S, Apoptosis: a review of programmed cell death, Toxicol. Pathol 35 (4) (2007) 495–516. [PubMed: 17562483]

[154]. Rathmell JC, Thompson CB, Pathways of apoptosis in lymphocyte development, homeostasis, and disease, Cell 109 (2) (2002) S97–S107. [PubMed: 11983156]

[155]. Meier P, Finch A, Evan G, Apoptosis in development, Nature 407 (6805) (2000) 796–801. [PubMed: 11048731]

[156]. Shao A, Wang Z, Wu H, Dong X, Li Y, Tu S, Tang J, Zhao M, Zhang J, Hong Y, Enhancement of autophagy by histone deacetylase inhibitor trichostatin a ameliorates neuronal apoptosis after subarachnoid hemorrhage in rats, Mol. Neurobiol 53 (1) (2016) 18–27. [PubMed: 25399954]

[157]. Reed JC, Apoptosis-based therapies, Nat. Rev. Drug Discov 1 (2) (2002) 111–121. [PubMed: 12120092]

[158]. Kroemer G, Galluzzi L, Brenner C, Mitochondrial membrane permeabilization in cell death, Physiol. Rev 87 (1) (2007) 99–163. [PubMed: 17237344]

[159]. Adams JM, Ways of dying: multiple pathways to apoptosis, Genes Dev. 17 (20) (2003) 2481–2495. [PubMed: 14561771]

[160]. Culmsee C, Zhu C, Landshamer S, Becattini B, Wagner E, Pellecchia M, Blomgren K, Plesnila N, Apoptosis-inducing factor triggered by poly (ADP-ribose) polymerase and Bid mediates neuronal cell death after oxygen-glucose deprivation and focal cerebral ischemia, J. Neurosci 25 (44) (2005) 10262–10272. [PubMed: 16267234]
[161]. Broughton BR, Reutens DC, Sobey CG. Apoptotic mechanisms after cerebral ischemia, Stroke 40 (5) (2009) e331–e339. [PubMed: 19182083]

[162]. Cardoso AL, Guedes JR, Pereira de Almeida L, Pedroso de Lima MC. miR-155 modulates microglia-mediated immune response by down-regulating SOCS-1 and promoting cytokine and nitric oxide production. Immunology 135 (1) (2012) 73–88. [PubMed: 22043967]

[163]. Peng Z, Li J, Li Y, Yang X, Feng S, Han S, Li J. Downregulation of miR-181b in mouse brain following ischemic stroke induces neuroprotection against ischemic injury through targeting heat shock protein A5 and ubiquitin carboxyl-terminal hydrolase isozyme L1. J. Neurosci. Res 91 (10) (2013) 1349–1362. [PubMed: 23900885]

[164]. Liu D-Z, Tian Y, Ander BP, Xu H, Stamova BS, Zhan X, Turner RJ, Ickling G, Sharp FR. Brain and blood microRNA expression profiling of ischemic stroke, intracerebral hemorrhage, and kainate seizures. J. Cereb. Blood Flow Metab 30 (1) (2010) 92–101. [PubMed: 19724284]

[165]. Zhang L, Zhang S, Yao J, Lowery FJ, Zhang Q, Huang WC, Li P, Li M, Wang X, Zhang C, Wang H, Ellis K, Cheerathodi M, McCarty JH, Palmieri D, Saunus J, Lakhani S, Huang S, Sahin AA, Aldepe KD, Steeg PS, Yu D. Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth, Nature 527 (7576) (2015) 100–104. [PubMed: 26479035]

[166]. Zhai F, Zhang X, Guan Y, Yang X, Li Y, Song G, Guan L. Expression profiles of microRNAs after focal cerebral ischemia/reperfusion injury in rats, Neuroal Regen. Res 7 (12) (2012) 917–923. [PubMed: 25722676]

[167]. Xu W, Gao L, Zheng J, Li T, Shao A, Reis C, Chen S, Zhang J. The roles of microRNAs in stroke: possible therapeutic targets, Cell Transplant. 27 (12) (2018) 1778–1788. [PubMed: 29871520]

[168]. Valko M, Leibfritz D, Moncol J, Cronin MTD, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease, Int. J. Biochem. Cell Biol 39 (1) (2007) 44–84. [PubMed: 16978905]

[169]. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, Lee VM. Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions, Science 290 (5493) (2000) 985–989. [PubMed: 11062131]

[170]. Gasche Y, Copin JC, Sugawara T, Fujimura M, Chan PH. Matrix metalloproteinase inhibition prevents oxidative stress-associated blood-brain barrier disruption after transient focal cerebral ischemia, J. Cereb. Blood Flow. Metab 21 (12) (2001) 1393–1400. [PubMed: 11740200]

[171]. Cherubini A, Ruggiero C, Polidori MC, Mecocci P. Potential markers of oxidative stress in stroke, Free Radic. Biol. Med 39 (7) (2005) 841–852. [PubMed: 16140205]

[172]. Lafon-Cazal M, Pietri S, Culcasi M, Bockaert J, JQ, Lee VM. Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions, Science 290 (5493) (2000) 985–989. [PubMed: 11062131]

[173]. Cuzzocrea S, et al., Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury, Pharmacol. Rev 53 (1) (2001) 135–159. [PubMed: 11171943]

[174]. Coyle JT, Puttfarken P. Oxidative stress, glutamate, and neurodegenerative disorders, Science 262 (5134) (1993) 689–695. [PubMed: 7901908]

[175]. Piantadosi CA, Zhang J. Mitochondrial generation of reactive oxygen species after brain ischemia in the rat, Stroke 27 (2) (1996) 327–332. [PubMed: 8571432]

[176]. Spranger M, Krempien S, Schwab S, Donneberg S, Hacke W, Superoxide dismutase activity in serum of patients with acute cerebral ischemic injury: correlation with clinical course and infarct size, Stroke 28 (12) (1997) 2425–2428. [PubMed: 9412626]

[177]. Gariballa S, Hutchin T, Sinclair A. Antioxidant capacity after acute ischaemic stroke, Qjm 95 (10) (2002) 685–690. [PubMed: 12324641]

[178]. Johnson JA, Johnson DA, Kraft AD, Calkins MJ, Jakel RJ, Vargas MR, Chen PC, The Nrf2-ARE pathway: an indicator and modulator of oxidative stress in neurodegeneration, Ann. N. Y. Acad. Sci 1147 (2008) 61–69. [PubMed: 19076431]

[179]. Papp D, Lenti K, Módos D, Fazekas D, Dül Z, Türei D, Földvári-Nagy L, Nussinov R, Csermely P, Korcsmáros T, The NRF2–related interactome and regulome contain multifunctional
proteins and fine-tuned autoregulatory loops, FEBS Lett. 586 (13) (2012) 1795–1802. [PubMed: 22641035]

[180]. Wang P, Liang X, Lu Y, Zhao X, Liang J, MicroRNA-93 downregulation ameliorates cerebral ischemic injury through the Nrf2/HO-1 defense pathway, Neurochem. Res 41 (10) (2016) 2627–2635. [PubMed: 27300700]

[181]. Liu P, Zhao H, Wang R, Wang P, Tao Z, Gao L, Yan F, Liu X, Yu S, Ji X, Luo Y, MicroRNA-424 protects against focal cerebral ischemia and reperfusion injury in mice by suppressing oxidative stress, Stroke 46 (2) (2015) 513–519. [PubMed: 25523055]

[182]. Zhao H, Tao Z, Wang R, Liu P, Yan F, Li J, Zhang C, Ji X, Luo Y, MicroRNA-23a-3p attenuates oxidative stress injury in a mouse model of focal cerebral ischemia-reperfusion, Brain Res. 1592 (2014) 65–72. [PubMed: 25280466]

[183]. Li P, Shen M, Gao F, Wu J, Zhang J, Teng F, Zhang C, An antagonir to microRNA-106b-5p ameliorates cerebral ischemia and reperfusion injury in rats via inhibiting apoptosis and oxidative stress, Mol. Neurobiol 54 (4) (2017) 2901–2921. [PubMed: 27023223]

[184]. Dharap A, Bowen K, Place R, Li LC, Vemuganti R, Transient focal ischemia induces extensive temporal changes in rat cerebral microRNAome, J. Cereb. Blood Flow Metab 29 (4) (2009) 675–687. [PubMed: 19142192]

[185]. Xu W, Li F, Liu Z, Xu Z, Sun B, Cao J, Liu Y, MicroRNA-27b inhibition promotes Nrf2/ARE pathway activation and alleviates intracerebral hemorrhage-induced brain injury, Oncotarget 8 (41) (2017) 70669–70684. [PubMed: 29050310]

[186]. Zhang RL, Chopp M, Roberts C, Liu X, Wei M, Nejad-Davarani SP, Wang X, Zhang ZG, Stroke increases neural stem cells and angiogenesis in the neurogenic niche of the adult mouse, PLoS One 9 (12) (2014), 113972.

[187]. Wu F, Yang Z, Li G, Role of specific microRNAs for endothelial function and angiogenesis, Biochem. Biophys. Res. Commun 386 (4) (2009) 549–553. [PubMed: 19540203]

[188]. Ma X-L, Li S-Y, Shang F, Effect of microRNA-129-5p targeting HMGB1-RAGE signaling pathway on revascularization in a collagenase-induced intracerebral hemorrhage rat model, Biomed. Pharmacother 93 (2017) 238–244. [PubMed: 28645008]

[189]. Li M, Zhang J, Circulating MicroRNAs: potential and emerging biomarkers for diagnosis of cardiovascular and cerebrovascular diseases, BioMed Res. Int 2015 (2015) 1–9.

[190]. Cheng YD, Al-Khoury L, Zivin JA, Neuroprotection for ischemic stroke: two decades of success and failure, NeuroRx 1 (1) (2004) 36–45. [PubMed: 15717006]

[191]. Melissos N, Huang HS, Grigorenko A, Rogaev E, Akbarian S, A set of differentially expressed miRNAs, including miR-30a-5p, act as posttranscriptional inhibitors of BDNF in prefrontal cortex, Hum. Mol. Genet 17 (19) (2008) 3030–3042. [PubMed: 18632683]

[192]. Dharap A, Bowen K, Place R, Li LC, Vemuganti R, Transient focal ischemia induces extensive temporal changes in rat cerebral microRNAome, J. Cereb. Blood Flow Metab 29 (4) (2009) 675–687. [PubMed: 19142192]

[193]. Liu FJ, Lim KY, Kaur P, Sepramanian S, Armugam A, Wong PT, Jeyaseelan K, microRNAs involved in regulating spontaneous recovery in embolic stroke model, PLoS One 8 (6) (2013) 66393.

[194]. Chen J, Ning R, Zacharek A, Cui C, Cui X, Yan T, Venkat P, Zhang Y, Chopp M, MiR-126 contributes to human umbilical cord blood cell-induced neurorestorative effects after stroke in type-2 diabetic mice, Stem Cells 34 (1) (2016) 102–113. [PubMed: 26299579]

[195]. Lusardi TA, Murphy SJ, Phillips JJ, Chen Y, Davis CM, Young JM, Thompson SJ, Saugstad JA, MicroRNA responses to focal cerebral ischemia in male and female mouse brain, Front. Mol. Neurosci 7 (2014) 11. [PubMed: 24574964]

[196]. Tan JR, Tan KS, Koo YX, Yong FL, Wang CW, Armugam A, Jeyaseelan K, Blood microRNAs in low or no risk ischemic stroke patients, Int. J. Mol. Sci 14 (1) (2013) 2072–2084. [PubMed: 23340648]

[197]. Wu P, Zuo X, Ji A, Stroke-induced microRNAs: The potential therapeutic role for stroke, Exp. Ther. Med 3 (4) (2012) 571–576. [PubMed: 22969931]
[198]. Long G, Wang F, Li H, Yin Z, Sandip C, Lou Y, Wang Y, Chen C, Wang DW, Circulating miR-30a, miR-126 and let-7b as biomarker for ischemic stroke in humans, BMC Neurol. 13 (2013) 178. [PubMed: 24237608]

[199]. Tan KS, Armugam A, Sepramaniam S, Lim KY, Setyowati KD, Wang CW, Jeyaseelan K, Expression profile of MicroRNAs in young stroke patients, PLoS One 4 (11) (2009) 7689.

[200]. Jeyaseelan K, Lim KY, Armugam A, MicroRNA expression in the blood and brain of rats subjected to transient focal ischemia by middle cerebral artery occlusion, Stroke 39 (3) (2008) 959–966. [PubMed: 18258830]

[201]. Selvamani A, Williams MH, Miranda RC, Sohrabji F, Circulating miRNA profiles provide a biomarker for severity of stroke outcomes associated with age and sex in a rat model, Clin. Sci 127 (2) (2014) 77–89.

[202]. Dharap A, Bowen K, Place R, Li LC, Vemuganti R, Transient focal ischemia induces extensive temporal changes in rat cerebral microRNAome, J. Cereb. Blood Flow Metab 29 (4) (2009) 675–687. [PubMed: 19142192]

[203]. Liu DZ, Tian Y, Ander BP, Xu H, Samova BS, Zhan X, Turner RJ, Jickling G, Sharp FR, Brain and blood microRNA expression profiling of ischemic stroke, intracerebral hemorrhage, and kainate seizures, J. Cereb. Blood Flow Metab 30 (1) (2010) 92–101. [PubMed: 19724284]

[204]. Ghosh G, Subramanian IV, Adhikari N, Zhang X, Joshi HP, Basi D, Chandrashekhar YS, Hall JL, Roy S, Zeng Y, Ramakrishnan S, Hypoxia-induced microRNA-424 expression in human endothelial cells regulates HIF-alpha isoforms and promotes angiogenesis, J. Clin. Invest 120 (11) (2010) 4141–4154. [PubMed: 20972335]

[205]. Laterza OF, Lim L, Garrett-Engele PW, Vlasakova K, Muniappa N, Tanaka WK, Johnson JM, Sina JF, Fure TL, Sistare FD, Glaab WE, Plasma MicroRNAs as sensitive and specific biomarkers of tissue injury, Clin. Chem 55 (11) (2009) 1977–1983. [PubMed: 19745058]

[206]. Weng H, Shen C, Hirokawa G, Ji X, Takahashi R, Shimada K, Kishimoto C, Iwai N, Plasma miR-124 as a biomarker for cerebral infarction, Biomed. Res 32 (2) (2011) 135–141. [PubMed: 21551949]

[207]. Lopez-Verrilli MA, Exosomes: mediators of communication in eukaryotes, Biol. Res 46 (1) (2013) 5–11. [PubMed: 23760408]

[208]. Simons M, Raposo G, Exosomes–vesicular carriers for intercellular communication, Curr. Opin. Cell Biol 21 (4) (2009) 575–581. [PubMed: 19442504]

[209]. Mianehsaz E, Mirzaei HR, Mahjoubin-Tehran M, Rezaee A, Sahemnasagh R, Pourhanifeh MH, Mirzaei H, Hamblin MR, Mesenchymal stem cell-derived exosomes: a new therapeutic approach to osteoarthritis?, Stem Cell Res. Ther 10 (1) (2019) 340. [PubMed: 31753036]

[210]. Luarte A, Bátiz LF, Wyneken U, Lafourcade C, Potential therapies by stem cell-derived exosomes in CNS diseases: focusing on the neurogenic niche, Stem Cells Int. 2016 (2016), 5736059. [PubMed: 27195011]

[211]. Xin H, Li Y, Chopp M, Exosomes/miRNAs as mediating cell-based therapy of stroke, Front. Cell. Neurosci 8 (2014) 377. [PubMed: 25426026]

[212]. Théry C, et al., Isolation and characterization of Exosomes from cell culture supernatants and biological fluids. Curr Curr Protoc Cell Biol Chapter 3: Unit 3.22. 2006.

[213]. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JI, Lötvall JO, Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells, Nat. Cell Biol 9 (6) (2007) 654–659. [PubMed: 17486113]

[214]. Gholeyshy A, Khosravi A, Ghaemmaghami A, Exosomal microRNA and stroke: a review. J. Cell Biochem 120 (10) (2019) 16352–16361. [PubMed: 31219202]

[215]. Emanuei C, Shearn AI, Angelini GD, Sahoo S, Exosomes and exosomal miRNAs in cardiovascular protection and repair, Vascul. Pharmacol 71 (2015) 24–30. [PubMed: 25869502]

[216]. Sun Z, Shi K, Yang S, Liu J, Zhou Q, Wang G, Song J, Li Z, Zhang Z, Yuan W, Effect of exosomal miRNA on cancer biology and clinical applications, Mol. Cancer 17 (1) (2018) 147. [PubMed: 30309355]

[217]. Choi DS, Kim DK, Kim YK, Gho YS, Proteomics of extracellular vesicles: exosomes and ectosomes, Mass Spectrom. Rev 34 (4) (2015) 474–490. [PubMed: 24421117]
[218]. Théry C, Ostrowski M, Segura E, Membrane vesicles as conveyors of immune responses, Nat. Rev. Immunol 9 (8) (2009) 581–593. [PubMed: 19498381]

[219]. Lakkaraju A, Rodriguez-Boulan E, Itinerant exosomes: emerging roles in cell and tissue polarity, Trends Cell Biol. 18 (5) (2008) 199–209. [PubMed: 18396047]

[220]. Ling H, Fabbri M, Calin GA, MicroRNAs and other non-coding RNAs as targets for anticancer drug development, Nat. Rev. Drug Discov 12 (11) (2013) 847–865. [PubMed: 24172333]

[221]. Lai CP-K, Breakefield XO, Role of exosomes/microvesicles in the nervous system and use in emerging therapies, Front. Physiol 3 (2012) 228. [PubMed: 22754538]

[222]. Frühbeis C, et al., Extracellular vesicles as mediators of neuron-glia communication. Front. Cell Neurosci, 2013; 7: 182; 2013.

[223]. György B, Hung ME, Breakefield XO, Leonard JN, Therapeutic applications of extracellular vesicles: clinical promise and open questions, Annu. Rev. Pharmacol. Toxicol 55 (2015) 439–464. [PubMed: 25292428]

[224]. Perez-Gonzalez R, Gauthier SA, Kumar A, Levy E, The exosome secretory pathway transports amyloid precursor protein carboxyl-terminal fragments from the cell into the brain extracellular space, J. Biol. Chem 287 (51) (2012) 43108–43115. [PubMed: 23129776]

[225]. Banigan MG, Kao PF, Kozubek JA, Winslow AR, Medina J, Costa J, Schmitt A, Schneider A, Cabral H, Caghal-Getkin O, Vanderburg CR, Delalle I, Differential expression of exosomal microRNAs in prefrontal cortices of schizophrenia and bipolar disorder patients, PLoS One 8 (1) (2013) e48814.

[226]. Rajendran L, et al., Alzheimer’s disease β-amyloid peptides are released in association with exosomes, Proc. Natl. Acad. Sci. USA 103 (30) (2006) 11172–11177. [PubMed: 16837572]

[227]. Dinkins MB, Dasgupta S, Wang G, Zhu G, Bieberich E, Exosome reduction in vivo is associated with lower amyloid plaque load in the 5XFAD mouse model of Alzheimer’s disease, Neurobiol. Aging 35 (8) (2014) 1792–1800. [PubMed: 24650793]

[228]. Gareev I, Yang G, Sun J, Beyelerli O, Chen X, Zhang D, Zhao B, Zhang R, Sun Z, Yang Q, Li L, Pavlov V, Safin S, Zhao S, Circulating MicroRNAs as potential noninvasive biomarkers of spontaneous intracerebral hemorrhage, World Neurosurg. 133 (2020) e369–e375. [PubMed: 31525485]

[229]. Ouyang Y, Li D, Wang H, Wan Z, Luo Q, Zhong Y, Yin M, Qing Z, Li Z, Bao B, Chen Z, Yin X, Zhu LQ, MiR-21–5p/dual-specificity phosphatase 8 signalling mediates the anti-inflammatory effect of haem oxygenase-1 in aged intracerebral haemorrhage rats, Aging Cell 18 (6) (2019) 13022.

[230]. Yang W, Zhang J, Xu B, He Y, Liu W, Li J, Zhang S, Lin X, Su D, Wu T, Li J, Hu-MSC-derived exosomes mitigate the age-related retardation of fertility in female mice, Mol. Ther. J. Am. Soc. Gene Ther 28 (2020) 1200–1213.

[231]. Baglio SR, Rooijers K, Koppers-Lalic D, Verweij FJ, Pérez Lanzón M, Zini N, Naaijens B, Perut F, Niessen HW, Baldini N, Pegtel DM, Human bone marrow–adipose-mesenchymal stem cells secrete exosomes enriched in distinctive miRNA and tRNA species, Stem Cell Res. Ther 6 (1) (2015) 127. [PubMed: 26129847]

[232]. Xie Y, Chu A, Feng Y, Chen L, Shao Y, Luo Q, Deng X, Wu M, Shi X, Chen Y, MicroRNA-146a: a comprehensive indicator of inflammation and oxidative stress status induced in the brain of chronic T2DM rats, Front. Pharmacol 9 (2018) 478. [PubMed: 29867484]

[233]. Chu B, Zhou Y, Zhai H, Li L, Sun L, Li Y, The role of microRNA-146a in regulating the expression of IRAK1 in cerebral ischemia–reperfusion injury, Can. J. Physiol. Pharmacol 96 (6) (2018) 611–617. [PubMed: 29505740]

[234]. Qu X, Wang N, Cheng W, Xue Y, Chen W, Qi M, MicroRNA-146a protects against intracerebral hemorrhage by inhibiting inflammation and oxidative stress, Exp. Ther. Med 18 (5) (2019) 3920–3928. [PubMed: 31656540]

[235]. Zhang H, Lu M, Zhang X, Kuai Y, Mei Y, Tan Q, Zhong K, Sun X, Tan W, Isosteviol Sodium Protects against Ischemic Stroke by Modulating Microglia/Macrophage Polarization via Disruption of GASS/miR-146a-5p sponge, Sci. Rep 9 (1) (2019) 12221. [PubMed: 31434993]

Biomed Pharmacother. Author manuscript; available in PMC 2021 August 01.
[236]. Hu YL, Wang H, Huang Q, Wang G, Zhang HB, MicroRNA-23a-3p promotes the perihematomatic edema formation after intracerebral hemorrhage via ZO-1, Eur. Rev. Med Pharmacol. Sci 22 (9) (2018) 2809–2816. [PubMed: 29771433]

[237]. Duan S, Wang F, Cao J, Wang C, Exosomes derived from microRNA-146a-5p-enriched bone marrow mesenchymal stem cells alleviate intracerebral hemorrhage by inhibiting neuronal apoptosis and microglial M1 polarization, Drug Des. Dev. Ther 14 (2020) 3143–3158.

[238]. Péron S, Berninger B, Imported stem cells strike against stroke, Cell Stem Cell 17 (5) (2015) 501–502. [PubMed: 26544109]

[239]. Boldrini M, Fulmore CA, Tatt AN, Simeon LR, Pavlova I, Rosoklija GB, Stankov A, Arango V, Dwork AJ, Hen R, Mann JJ, Human hippocampal neurogenesis persists throughout aging, Cell Stem Cell 22 (4) (2018) 589–599. e5. [PubMed: 29625071]

[240]. Yamashita T, Ninomiya M, Hernández-Acosta P, García-Verdugo JM, Sunabori T, Sakaguchi M, Adachi K, Kojima T, Hirota Y, Kawase T, Araki N, Abe K, Okano H, Sawamoto K, Subventricular zone-derived neuroblasts migrate and differentiate into mature neurons in the post-stroke adult striatum, J. Neurosci 26 (24) (2006) 6627–6636. [PubMed: 16775151]

[241]. Ngalula KP, Cramer N, Schell MJ, Juliano SL, Transplanted neural progenitor cells from distinct sources migrate differentially in an organotypic model of brain injury, Front. Neurol 6 (2015) 212. [PubMed: 26500604]

[242]. Zhang S, Jin T, Wang L, Liu W, Zhang Y, Zheng Y, Lin Y, Yang M, He X, Lin H, Chen L, Tao J, Electro-acupuncture promotes the differentiation of endogenous neural stem cells via exosomal microRNA 146b after ischemic stroke, Front. Cell Neurosci 14 (2020) 223. [PubMed: 32792909]

[243]. Xi T, Jin F, Zhu Y, Wang J, Tang L, Wang Y, Liebeskind DS, He Z, MicroRNA-126-3p attenuates blood-brain barrier disruption, cerebral edema and neuronal injury following intracerebral hemorrhage by regulating PIK3R2 and Akt, Biochem. Biophys. Res. Commun 494 (1–2) (2017) 144–151. [PubMed: 29042193]

[244]. Harris TA, et al., MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1, Proc. Natl. Acad. Sci. USA 105 (5) (2008) 1516–1521. [PubMed: 18227515]

[245]. Lasek-Bal A, et al., The importance of selected markers of inflammation and blood-brain barrier damage for short-term ischemic stroke prognosis, J. Physiol. Pharmacol 70 (2019) 2.

[246]. Garcia-Bonilla L, Benakis C, Moore J, Iadecola C, Anrather J, Immune mechanisms in cerebral ischemic tolerance, Front. Neurosci 8 (2014) 44. [PubMed: 24624056]

[247]. Dock H, Theodorsson A, Theodorsson E, DNA methylation inhibitor zebaruline confers stroke protection in ischemic rats, Transl. Stroke Res 6 (4) (2015) 296–300. [PubMed: 25824538]

[248]. Endres M, Meisel A, Biniszkiwicz D, Namura S, Prass K, Ruscher K, Lipski A, Jaenisch R, Moskowitz MA, Dimagi U, DNA methyltransferase contributes to delayed ischemic brain injury, J. Neurosci 20 (9) (2000) 3175–3181. [PubMed: 10777781]

[249]. Pandi G, Nakka VP, Dharap A, Roopra A, Venuganti R, MicroRNA miR-29c down-regulation leading to de-repression of its target DNA methyltransferase 3a promotes ischemic brain damage, PLoS One 8 (3) (2013) 58039.

[250]. Hu Z, Zhong B, Tan J, Chen C, Lei Q, Zeng L, The emerging role of epigenetics in cerebral ischemia, Mol. Neurobiol 54 (3) (2017) 1887–1905. [PubMed: 26894397]

[251]. Elliott EN, Sheaffer KL, Kaestner KH, The ‘de novo’ DNA methyltransferase Dnmt3b compensates the Dnmt1-deficient intestinal epithelium, Elife 5 (2016), e12975. [PubMed: 26808831]

[252]. Cui J, Liu N, Chang Z, Gao Y, Bao M, Xie Y, Xu W, Liu X, Jiang S, Liu Y, Shi R, Xie W, Jia X, Shi J, Ren C, Gong K, Zhang C, Bade R, Shao G, Ji X, Exosomal MicroRNA-126 from RIPC serum is involved in hypoxia tolerance in SH-SY5Y cells by downregulating Dnmt3B, Mol. Ther. Nucleic Acids 20 (2020) 649–660. [PubMed: 32380415]

[253]. Xin H, Katakowksi M, Wang F, Qian JY, Liu XS, Ali MM, Buller B, Zhang ZG, Chopp M, MicroRNA cluster miR-17–92 cluster in exosomes enhance neuroplasticity and functional recovery after stroke in rats, Stroke 48 (3) (2017) 747–753. [PubMed: 28232590]

[254]. Xin H, Li Y, Liu Z, Wang X, Shang X, Cui Y, Zhang ZG, Chopp M, MiR-133b promotes neural plasticity and functional recovery after treatment of stroke with multipotent mesenchymal
stromal cells in rats via transfer of exosome-enriched extracellular particles, Stem Cells 31 (12) (2013) 2737–2746. [PubMed: 23630198]

[255]. Xin H, Wang F, Li Y, Lu QE, Cheung WL, Zhang Y, Zhang ZG, Chopp M, Secondary release of exosomes from astrocytes contributes to the increase in neural plasticity and improvement of functional recovery after stroke in rats treated with exosomes harvested from microRNA 133b-overexpressing multipotent mesenchymal stromal cells, Cell Transpl. 26 (2) (2017) 243–257.

[256]. Jiang M, Wang H, Jin M, Yang X, Ji H, Jiang Y, Zhang H, Wu F, Wu G, Lai X, Cai L, Hu R, Xu L, Li L, Exosomes from MiR-30d-5p-ADSCs reverse acute ischemic stroke-induced, autophagy-mediated brain injury by promoting M2 microglial/macrophage polarization, Cell Physiol. Biochem 47 (2) (2018) 864–878. [PubMed: 29807362]

[257]. Venkat P, Cui C, Chopp M, Zacharek A, Wang F, Landschoot-Ward J, Shen Y, Chen J, MiR-126 mediates brain endothelial cell exosome treatment-induced neurorestorative effects after stroke in type 2 diabetes mellitus mice, Stroke 50 (10) (2019) 2865–2874. [PubMed: 31394992]

[258]. Song H, Zhang X, Chen R, Miao J, Wang L, Cui L, Ji H, Liu Y, Cortical neuron-derived exosomal microRNA-181c-3p inhibits neuroinflammation by downregulating CXCL1 in astrocytes of a rat model with ischemic brain injury, Neuroimmunomodulation 26 (5) (2019) 217–233. [PubMed: 31665717]

[259]. Deng Y, Chen D, Gao F, Lv H, Zhang G, Sun X, Liu L, Mo D, Ma N, Song L, Huo X, Yan T, Zhang J, Miao Z, Exosomes derived from microRNA-138-5p-overexpressing bone marrow-derived mesenchymal stem cells confer neuroprotection to astrocytes following ischemic stroke via inhibition of LCN2, J. Biol. Eng 13 (2019) 71. [PubMed: 31485266]

[260]. Yang J, Zhang X, Chen X, Wang L, Yang G, Exosome mediated delivery of miR-124 promotes neurogenesis after ischemia, Mol. Ther. Nucleic Acids 7 (2017) 278–287. [PubMed: 28624203]

[261]. Ling X, Zhang G, Xia Y, Zhu Q, Zhang J, Li Q, Niu X, Hu G, Yang Y, Wang Y, Deng Z, Exosomes from human urine-derived stem cells enhanced neurogenesis via miR-26a/HDAC6 axis after ischaemic stroke, J. Cell. Mol. Med 24 (1) (2020) 640–654. [PubMed: 31667951]

[262]. Correction to: MicroRNA-17–92 Cluster in Exosomes Enhance Neuroplasticity and Functional Recovery After Stroke in Rats. Stroke, 2017. 48(5): p. e137. [PubMed: 28439044]

[263]. Yang J, Zhang X, Chen X, Wang L, Yang G, Exosome mediated delivery of miR-124 promotes neurogenesis after ischemia, Mol. Ther.-Nucleic Acids 7 (2017) 278–287. [PubMed: 28624203]

[264]. Liu W, Wu J, Huang J, Zhao P, Lin Y, Wang L, Lin R, Chen L, Tao J, Electroacupuncture regulates hippocampal synaptic plasticity via miR-134-mediated LIMK1 function in rats with ischemic stroke, Neural Plast. 2017. 2017: p. e137. [PubMed: 28439044]

[265]. Huang X, Yuan T, Tschannen M, Sun Z, Jacob H, Du M, Liang M, Dittmar RL, Liu Y, Liang M, Kohli M, Thibodeau SN, Boardman L, Wang L, Characterization of human plasma-derived exosomal RNAs by deep sequencing, BMC Genom. 14 (2013) 319.

[266]. Xu X, Zhuang C, Chen L, Exosomal long non-coding RNA expression from serum of patients with acute minor stroke, Neuropsychiatr. Dis. Treat 16 (2020) 153–160. [PubMed: 32021207]

[267]. Chen HS, Tong HS, Zhao Y, Hong CY, Bin JP, Su L, Differential expression pattern of exosome long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) in vascular endothelial cells under heat stroke, Med. Sci. Monit 24 (2018) 7965–7974. [PubMed: 30399613]
Fig. 1.
Biogenesis of lncRNAs. lncRNA transcripts are classified based on their genomic location in relation to the closest gene including antisense lncRNAs, sense lncRNAs, intronic lncRNAs, enhancer lncRNAs and intergenic lncRNAs.
Fig. 2.
Different lncRNAs involved in stroke pathogenesis. This figure is adapted from [82].
Fig. 3.
Various microRNAs involved in stroke pathogenesis.
Fig. 4.
Potent exosome mediated inter-cellular communications in the brain re-modeling following the strokes. As seen, the exosomes transfer RNAs as well as proteins for influencing angiogenesis, oligo-dendrogenesis, EVs, extra-cellular vesicles and neurogenesis.
### Table 1

Selected lncRNAs involved in stroke pathogenesis.

| LncRNA | Target(s) | Effect(s) | Study models | Ref  |
|--------|-----------|-----------|--------------|------|
| N1LR   | Maybe inactivates p53 | Inhibits neural death and apoptosis probably via reducing p53 phosphorylation | In vitro: N2a cells In vivo: SD rats, mice | [76] |
| MALAT1 | E-selectin and Bim | Inhibits inflammation and endothelial cell death and defends cerebral parenchyma and microvasculature from brain ischemic injury. | In vitro: BMECs In vivo: C57BL/6 mice | [83] |
| H19    | DUSP5-ERK1/2 | Silenced autophagy which activated by OGD/R via DUSP5-ERK1/2 axis. | In vitro: SH-SY5Y cells In vivo: SD rats | [84] |
| TUG1   | miR-9/Bcl2l11 | Inhibits miR-9 and weakened suppression of bcl2l11 expression and so, leads a neurotoxicity after stroke. | In vitro: SH-SY5Y cells In vivo: SD rats | [85] |
| C2dat1 | CaMKIIδ | Increases the CaMKIIδ expression and activates NF-κB signal impacting neuronal survival after ischemic stroke. | In vitro: N2a cells In vivo: C57BL/6 mice | [86] |
| ANRIL  | VEGF/NF-κB | Increases VEGF expression and activates angiogenesis via activation of NF-κB pathway | In vivo: male Wistar rats | [87] |
### Table 2

Different microRNAs involving in stroke.

| MicroRNA (s) | Expression status | Target (s)/Mechanism (s) | Study model | Ref |
|--------------|-------------------|--------------------------|-------------|-----|
| miR-296-5p   | Down              | CD73, PKN2               | Mouse/MCAO  | [195]|
| miR-686, miR-1224 | Up             | CD73, PKN2               | Mouse/MCAO  | [195]|
| miR-498, miR-25, miR-483-5p, miR-34b | Down | BCL-2 modifying factor (BMF) and p53 | Human/Ischemic stroke | [196]|
| miR-21       | Up                | SOD3, TNF-α              | Rat/MCAO    | [197]|
| mir-30a      | Down              | RhoB, beclin-1           | Human       | [198]|
| mir-126, mir-146 | Up              | V CAM-1, TLR4            | Human       | [199]|
| MiR-1259, miR-142-3p, miR-15b, miR-186, miR-519e, miR-768-5p | Down | Arl2 | Human | [199]|
| miR-1184, Let-7e, miR-1246, miR-1261, miR-1275, miR-1285, miR-1290, miR-181a, miR-25, miR-513a-5p, miR-550, miR-602, miR-665, miR-891, miR-933, miR-923 | Up | GPx1, NOX4 | Human | [199]|
| miR-16, miR-23a, miR-150, miR-107, miR-185, miR-191, miR-292-5p, Let-7, miR-451, miR-327 and miR-494 | Up | XIAP, APAF-1/caspase-9 | Rat/MCAO | [200]|
| miR-26a, miR-26b, miR-29b, miR-140, miR-214, miR-328, miR-352, miR-320, miR-137 | Down | NCX1 | Rat/MCAO | [200]|
| miR-19b, miR-136, miR-199a-3p, miR-32 | Up | PI3K/Akt/mTOR signaling | Rat/MCAO | [201]|
| miR-290, miR-218, miR-133, miR-145 | Up | Caspase-9, -3 superoxide dismutase-2 | Rat/MCAO | [202]|
| miR-27a, miR-204, miR-301, miR-338, miR-7, miR-137, miR-335, miR-148b, miR-98, miR-30e | Down | COXIV, SOD2, Txnrd2 | Rat/MCAO | [202]|
| miR-155      | Down              | SHIP1, p53               | Rat/MCAO    | [203]|
| miR-424      | Up                | Cul lin 2, PU.1, RUNX-1 and C/EBPα | Mice/MCAO  | [204]|
| miR-124      | Up                | VILIP-1                  | Rat/MCAO    | [205, 206]|
Table 3

Exosomal miRNAs in stroke.

| Cargo(s) Detection methods | Effect(s)                                                                 | References |
|----------------------------|--------------------------------------------------------------------------|------------|
| miR-17–92                  | Increases neural plasticity and functional recovery after stroke, possibly via targeting phosphatase and tensin homolog. | [253]      |
| MiR-133b                   | promotes neural plasticity and functional recovery after treatment of stroke | [254]      |
| miR-133b                   | improve neural plasticity and functional recovery after stroke           | [255]      |
| MiR-30d-5p                 | Prevent cerebral injury by inhibiting autophagy-mediated microglial polarization to M1. | [256]      |
| MiR-126                    | Promotes neurorestorative effects in T2DM mice.                         | [257]      |
| miR-181c-3p                | Inhibits Neuroinflammation by Downregulating CXCL1 in Astrocytes.        | [258]      |
| miR-138-5p                 | Reduces neurological impairment by promoting proliferation and inhibiting inflammatory responses of astrocytes following IS by targeting LCN2. | [259]      |
| miR-124                    | Promotes Neurogenesis                                                  | [260]      |
| microRNA-26a              | Enhanced neurogenesis after ischemic stroke.                            | [261]      |
| miR-146b                   | Improve neurological injury after ischemic stroke.                      | [242]      |
| MicroRNA-17-92             | Enhance Neuroplasticity and Functional Recovery After Stroke.           | [262]      |
| miR-146a-5p                | Inhibiting Neuronal Apoptosis and Microglial M1 Polarization.           | [237]      |
| miR-124                    | Cortical neurogenesis is increased.                                     | [263]      |
| miR-134                    | It enhanced expressing LIM domain kinase to increase plasticity of synaptic-dendritic after Ischemic stroke. | [264]      |